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Objectives: The primary objective was to describe the cutaneous manifestations and
nailfold dermoscopy in Scleroderma. The secondary objective was to study interleukin 6
levels in subset of diffuse systemic sclerosis patients.
Methodology: We recruited 35 patients between a study period of February 2014 to
September 2015. All patients were examined for cutaneous manifestation of systemic
sclerosis and dermoscopy of the nail fold capillary was performed using Heine delta 20
dermoscope. The severity of the disease was assessed using a Modified Rodnan Skin
score. In a subset of patients with diffuse systemic sclerosis interleukin -6 levels were
assessed. The prelevence was expressed in term of percentage along with 95%
confidence interval. The association of dermoscopic capillary pattern and Rodnan skin
score with various clinical manifestations was evaluated using χ² tests.
Results: In our study we had a female preponderance with 91% of patients with diffuse
type of disease. Cutaneous sclerosis was present in 97.1 % of our patients with upper
limb being the commonest site of involvement. Pigmanetary disturbances were
commoner in our study (94.3%) with commonest abnormality being salt and pepper
pigmentation. Commonent systemic manifestation was interstitial lung disease (74.3%).
The commonest pattern in nalifold dermoscopy was dilated capillaries (91.4%).
Scleroderma pattern was seen in 77.1% of our patients. Interleukin 6 was elevated in 2 of
7 of our patents.
1INTRODUCTION
Scleroderma is an autoimmune condition of unknown aetiology which can affect the
skin, blood vessels and internal organs. It was initially described in 1754 in a young
Italian woman who presented with progressive thickening of the skin.(1) The skin
involvement is a cardinal feature for the diagnosis of scleroderma. Other internal
organs which can be involved include the lungs, gastrointestinal system, heart and the
kidneys.
Scleroderma is classified into diffuse and limited type of disease based on the extent
of skin involvement. The skin involvement in systemic sclerosis can be varied. Apart
from the cutaneous sclerosis, the other skin manifestations include Raynaud’s
phenomenon, digital ulcers, gangrene, flexion contractures and telangiectasias. There
are various diagnostic criteria for the diagnosis of scleroderma, the commonly
followed one being the American College of Rheumatology (ACR) criteria. The
diffuse type of disease is associated with increased internal organ involvement and
worse prognosis. Scleroderma accounts for the highest proportion of mortality among
patients with connective tissue diseases. The main causes of death in scleroderma
include scleroderma renal crisis, pulmonary artery hypertension and pulmonary
fibrosis. Hence early diagnosis and initiation of therapy is of utmost importance in
improving the survival rates.(2)
Nail fold dermoscopy is a noninvasive technique which aids in the diagnosis of
scleroderma. Presence of abnormal nail fold capillaries has been given a score of 2 in
2the latest ACR- EULAR (American College of Rheumatology – European League
against Rheumatism) criteria in the diagnosis of scleroderma. Nail fold dermoscopy
helps in predicting the stage and extent of microvascular damage and also to
differentiate primary Raynaud’s phenomenon from Raynaud’s phenomenon
secondary to scleroderma and other related disorders. It also aids in the diagnosis of
early scleroderma prior to the onset of skin symptoms.(3)
There have been no published Indian studies on the pattern of nail fold dermoscopy
in scleroderma. Hence we conducted this study to look at the cutaneous profile and
nail fold dermoscopy in patients with systemic sclerosis.
3AIMS AND OBJECTIVES
Primary Objective
 To describe the cutaneous manifestations among scleroderma patients
 To study the nail fold dermoscopy findings and its correlation with
systemic manifestation in scleroderma patients
Secondary objective
To study the levels of interleukin-6 among a subset of patients with diffuse
systemic sclerosis
4REVIEW OF LITERATURE
INTRODUCTION
Scleroderma is an autoimmune connective tissue disease of unknown aetiology
which affects the skin, internal organs and blood vessels.(1) It is also referred to as
progressive systemic sclerosis, systemic sclerosis and acrosclerosis.(4) Skin is the
most commonly affected organ and cutaneous sclerosis is one of the  cardinal feature
for  the diagnosis of scleroderma.(2) It affects three major pathogenetic hallmarks
which include immune dysfunction, extensive skin fibrosis and vasculopathy. The
interaction between these hallmarks is still unknown. Scleroderma is a heterogeneous
disease with clinical features which vary from only cutaneous involvement to
extensive internal organ involvement.
HISTORY
The first case was described in 1754 in an Italian lady who had progressive
thickening of skin. Goetz postulated that scleroderma was a systemic disease and
coined the term progressive systemic sclerosis.(4)
EPIDEMIOLOGY
Overall prevalence of the disease is estimated to be 4 to 489 cases per million
individuals and incidence is 0.6 to 122 cases per million individuals.(5)(6) The
prevalence  in USA is estimated to be 240 per 1 million adults. The prevalence is
lower in Britain and Japan and is about 35 cases per 1 million persons.(6) There are
no standardised Indian studies on prevalence of the disease. The reported prevalence
5based on a study in north India by Minz et al. is 120 cases per million of which
Raynaud’s disease was present in 50 cases per million and 70 cases per million had
overlap disease. This study was a hospital based study on patients with ANA positive
connective tissue disorders. The limitation of the study was that there were no well
defined diagnostic criteria and the study was limited to north India.(7) Females were
more affected than males with ratios varying from 3:1 to 14:1.(2) The reported male
to female ratio in a previous Indian study by Sharma et al. was 1:5.2.(8) The male to
female ratio in Iceland and Japan was higher than the Indian study and was 1:8 and
1:16 respectively. The male to female ratio in Australia was 1:4.(8)(9)(10)(11) The
mean age of onset was 30 to 50 years with males having an earlier onset of the
disease.(2)
The racial factor influences both the disease type and susceptibility. Europeans,
white Americans and Australians more frequently have limited disease whereas
diffuse disease is more commonly seen in black American and some Asian
populations.(5) In a study by Pradhan et al. the prevalence of diffuse disease was
40.9% and limited disease was 29.1%.(12) Autoantibodies expression is also
influenced by genetic factors.(5) (13)(14) Laing et al. reported that anti-centromere
antibodies were commoner in white women (38%) compared to black women(17%)
whereas anti scl-70 had similar prevalence in both groups(18.4 vs. 18.6%).(13)
McNeilage et al. reported high prevalence of anti scl-70(76%)  in non white Thais as
compared to anticentromere(ACA) antibodies(4%).(14)
6Systemic sclerosis has the highest case specific mortality among all the connective
tissue disorder and is influenced by race and ethnicity, age, extracutaneous
involvement and disease subtype.(2)
The commonest cause of mortality is progressive pulmonary fibrosis; other causes
include pulmonary artery hypertension, severe gastrointestinal involvement and renal
crisis. Renal crisis accounts for early mortality in systemic sclerosis.(6) The survival
rate is dependent on the internal organ involvement and has improved over the past
years due to introduction of new drugs. The estimated 10 year survival rate is 70 to
80%.(6)(15)
PATHOGENESIS
The pathogenesis of scleroderma is not clearly understood and is said to be an
autoimmune disease involving the cellular and humoral immune system.(2)(1)(16)
The key pathogenetic changes are immune dysregulation with formation of auto
antibodies, vascular changes and fibrosis which is characterised by deposition of
collagen in the extracellular matrix.(1) The clinical heterogeneity is influenced by the
predominant pathogenetic mechanism in the affected patients.(2)
AETIOLOGY
The exact aetiology is not known and the factors include genetic, infectious and
environmental factors.(2) The diagrammatic representation of aetiology of
scleroderma is depicted in figure -1.
7Genetic factors
A positive family history contributes to 13 fold risk for acquisition of disease.(2)
Assasi et al. showed that families affected by scleroderma showed concordant auto
antibodies.(17) Monozygotic twins and dizygotic twins showed 90% and 40%
concordant auto antibodies respectively. Shared genes is gaining prominence in the
pathogenesis of scleroderma. Multiple genes in immune regulation which play a role
in pathogenesis of scleroderma include BANK1, IL-23R, IRF-5 and PTPN22.(18)
Studies have suggested an association of antifibrillarin positive patients with HLA-
DR1*1302, DQB1*0604/0605 halotype. Anti Pm-scl antibodies are associated with
HLA SRB1*03. STAT 4 gene is associated with both diffuse and limited disease.(19)
BANK-1 and IRF -5 alleles showed 1.43 increased risks for diffuse type of disease.
(20)
Infectious factors
Infections with Parvo virus B19, Human Papilloma Virus, Cytomegalovirus (CMV)
and toxoplasmosis is said to have a role as elevated antibodies have been detected in
a few patients.  It is attributed to possible molecular mimicry with autoimmune
response induction. (21)(20)
Environmental factors
Occupational exposure to chemicals like silica, vinyl chloride, trichloroethylene,
benzene carbon tetrachloride and epoxy resins have been implicated to cause
scleroderma.(22)(23)(24)(25)(26) Drugs causing scleroderma like disease include
bleomycin, cocaine and pentazocine. Radiation therapy can also be a contributing
8factor.  Smoking is an important factor which plays an important factor in induction
and maintenance mechanism of vascular changes.(20) Hypovitaminosis D was
associated inversely with skin severity, decreased DLCO levels and high pulmonary
artery pressure.(27)(28)
FIGURE -1: AETIOLOGY  OF SCLERODERMA (20)
Vascular Dysregulation
Vascular dysregulation is an early change in the pathogenesis of scleroderma
preceding fibrosis.(1)(29) The blood vessels affected range from the small capillaries
9in the proximal nail fold to the pulmonary arteries.(1) The primary event is vascular
injury and activation of vasoactive mediators.  Initial vascular injury is characterised
by endothelial injury which is mediated by various factors which include
environmental stress, proteolytic enzymes, cytokines, viruses and endothelial
directed auto antibodies.(20) The earliest sign is vasodilatation – vasoconstriction
imbalance leading to increased vascular permeability. Vasodilatation is mediated by
nitric oxide, calcitonin related gene peptide and prostacyclin. Vasoconstriction is
mediated by endothelin 1(ET-1), alpha-2 receptors and angiotensin II. Impaired
vasodilatation- vasoconstriction balance leads to impaired blood flow and tissue
hypoxia.(20)(2)
The endothelial activation causes expression of the cell adhesion molecules which
causes transendothelial migration and perivascular accumulation of both T and B
lymphocytes and macrophages. The inflammatory cells produce cytokines and
transforming growth factor beta (TGF-ß) along with endothelin factor-1 which leads
to an activation of myofibroblasts which leads to subendothelial fibrotic tissue along
with platelet aggregation and intravascular thrombosis. These changes lead to
microvascular occlusion.  In scleroderma, there is impaired neoangiogenesis which is
mediated by vascular endothelial growth factor (VEGF) and its receptor along with
TGF-ß. Transforming growth factor beta (TGF-ß) leads to accumulation of collagen
in extracellular matrix. Anti endothelial antibodies also contribute to endothelial
apoptosis.  Elevated levels of von Willebrand factor, fibrinogen and plasma proteins
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also contribute to micro-occlusion. Digital ulcers and Raynaud’s phenomenon is
attributed to reversible vasospasm along with arterial damage whereas renal crisis
and pulmonary artery hypertension are attributed to large vessel dysregulation.
(4)(20)(2)
Endothelin-1 is a strong vasoconstrictor which also has fibrotic properties. It
activates fibroblast collagen production along with leukocyte adhesion molecule
activation.  It has two receptors ET-A and ET-B of which ET-B is down regulated
causing vasoconstriction and fibrosis. Elevated levels of ET-1 are seen in patients
with minimal fibrosis with associated pulmonary hypertension and primary vascular
disease and in patient with the diffuse type of disease. Elevated ET-1 also correlates
with the severity of Raynaud’s phenomenon, digital ulcers, pulmonary hypertension
and renal crisis.(20)(30)(31)(32)(33)
Immune dysfunction
Immune dysfunction appears to play a role in the pathogenesis of systemic sclerosis
and affects both the humoral and cell mediated immunity.(1) The initial
inflammatory cells include T cells, B cells, mast cells and macrophages. In the later
stages the T lymphocytes are the predominant cells which lead to oligoclonal
expansion with a predominant Th2 response.  This is demonstrated by elevated levels
of Th-2 related cytokines in scleroderma patients which include interleukins 2, 4, 10,
13 and 17.
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Toll like receptors and non toll like receptor activation lead to the activation of B
cells which in turn activates interleukin 1 and 6 along with TGF-ß. These cytokines
lead to accumulation of collagen in the extracellular matrix which eventually leads to
fibrosis.(20)(2)
Evidence shows that interleukin 6 may be critical in the pathogenesis of systemic
sclerosis. Interleukin-6 (IL-6) is a pro-inflammatory cytokine which is an acute
phase protein and hence is elevated in the early stage of the disease. Interleukin
6 levels are elevated in diffuse and limited type of disease. Polymorphisms in the IL-6
gene may lead to an increase in susceptibility to develop systemic sclerosis. IL-6 and
fibrotic events may be mediated directly through transcriptional activation of
collagen. It may be mediated indirectly through the upregulation of other cytokines
acting in an autocrine manner. Addition of IL-6 to fibroblasts in the dermis leads to
upregulation of collagen which eventually leads to fibrosis. It is still unclear at a
molecular level how elevated IL-6 contributes to fibrosis. Elevated levels of  IL-6 were
also proportionate to skin thickness suggesting a possible causal relationship.(34)
Elevated IL-6 levels also correlated with antihistone antibody levels and levels decreased
with treatment.(35) Interleukin 6 also has a protective role in the gut mucosa and use of
IL-6 antagonists was associated with exacerbation of gastrointestinal symptoms.(36)
Increased IL-6 levels were also associated with avascular areas in dermoscopy which was
associated with higher incidence of the digital ulcers.(37) Increased IL-6 levels are also
associated with increased CRP levels which correlated with disease severity, decreased
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survival and worse outcome.(38) Studies are underway in developing anti IL-6 antibodies
as a possible therapeutic target.(39)
Auto-antibodies production
Majority(95%) of patients with scleroderma have positive auto antibodies which have
diagnostic and prognostic implications.(2)(28) Table 1 demonstrates the various auto-
antibodies associated with scleroderma and its clinical association.
TABLE 1: AUTO-ANTIBODIES IN SCLERODERMA(2)
AUTOANTIBODY CLINICAL ASSOCIATION
Scl -70 Diffuse type of diseasePulmonary fibrosis
secondary pulmonary artery hypertension
Anti centromere
Limited type
Isolated pulmonary artery hypertension
Calcinosis
Severe GI involvement
U1RNP Overlap features
Arthritis
RNAP-III Diffuse type
Renal crisis
Pm-scl Limited typeMyositis overlap
Calcinosis
Fibrillarin
Diffuse type
Pulmonary artery hypertension
Renal disease
Myositis
Th/To Limited type
Pulmonary fibrosis
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Fibrosis
Fibrosis is the final pathogenetic mechanism in the development of scleroderma
leading to collagen deposition in the extracellular matrix of the skin as well as internal
organs. The main contributor is the fibrogenetic fibroblasts.  The factors contributing
to inappropriate activation along with growth enhancers and down regulators are still
not clearly understood. There is up regulation of collagen types I, III, V, VI, VII and
XIV. This is mediated by cytokines like TGF-ß. Transforming growth factor -ß is
mitogenetic for fibroblasts and leads to accumulation of collagen, glycosamineglycans
and fibronectin. There is also increased expression of proteases like thrombin and
tryptase which leads to synthesis of matrix. There is down regulation of matrix
metalloproteinases (MMP) like MMP 3,7and 12 with elevation of tissue inhibitors of
metalloproteinases (TIMP) and presence of anti MMP auto antibodies. Transforming
growth factor -ß is also related to Connective Tissue Growth Factor (CTGF) which is a
strong inducer of collagen production and is important in maintenance of extracellular
matrix. Fibrillin-1 is seen in the dermis and fibrillin-2 is seen in the vascular tissue and
basement membrane. Autoantibodies are present against short fragment of fibrillin -1
which help in remodeling during fibrosis. Antibodies against fibrillin-2 are associated
with wnt pathway and TGF-ß.(40) Wnt pathway is associated with pulmonary
fibrosis.(41) In a study by Wei et al on a mouse model, wnt 10b was associated with
TGF-ß dependent dermal fibrosis and loss of adipose tissue.(42) Antibodies against
platelet derived growth factors (PDGF) receptor activate gene expression of collagen
14
and eventually lead to fibrosis. Other factors which contribute to fibrosis include
VEGF, ET-1, IL 13 and 21 and Monocyte chemoattractant Protein(MCP) protein.
Some evidence suggests that there is an autocrine mechanism leading to
hypersensitivity of growth factors in the scleroderma affected fibroblasts. Other
evidence suggest that normal fibroblasts when exposed to an abnormal
microenvironment leads to enhanced expression of growth factors which lead to
collagen synthesis. (2)(20)(43) Proteome wide analysis showed that CXCL4 is the
predominant protein secreted by plasmactytoid dendritic cells in scleroderma.(46)
CXCL4 can serve as a biomarkers for skin fibrosis and pulmonary fibrosis and also
predict the progression in patient with scleroderma phenotypes.(38) The interaction
between endothelial cells, fibroblasts and leucocytes are demonstrated in figure -2.
FIGURE 2: PATHOGENESIS
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CLASSIFICATION
Systemic sclerosis was classified by Leroy in 1988 based on the extent of skin
involvement as shown in figure 3.(44)
The limited type is characterized by involvement of the distal extremities and the
face.  The ADF (Arbeitsgruppe Dermatologische Forschung) classification is used in
limited acral disease, type 1 is defined as involvement up to ankle joint and hand and
type 2 is defined as involvement of more proximal limbs and face.(44) Barnett et al.
classified skin sclerosis as type I including sclerodactyly, type 2 as proximal to
metacarpophalangeal joint with no involvement of the trunk and type 3 includes
involvement of the trunk.(45) Limited disease is characterised by late organ
involvement and anti CENP antibodies positivity (50 to 90%) of patients.  A certain
subset of patients with limited type of systemic sclerosis have CREST syndrome
(calcinosis, Raynaud’s phenomenon, oesophageal involvement, sclerodactyly and
telangiectasia). Diffuse type of systemic sclerosis is characterised by early organ
involvement and anti Scl 70 positivity. Systemic sclerosis sine scleroderma refers to
Raynaud’s phenomenon with positive serology with no cutaneous involvement.
(4)(44) The differences between diffuse and limited disease are shown in table-2.
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FIGURE 3 – CLASSICATION
TABLE 2 : DIFFERENCES BETWEEN DIFFUSE AND LIMITED TYPE (2)
DIFFUSE LIMITED
Extent Extremities, face, trunk Extremities, face
Raynaud’s phenomenon Within 1 year Many years to decades
Organ involvement Early Late
Tendon friction rub Present Absent
Antibodies
Anti topoisomerase -I(30 to
40%)
Anti CENP (50 to 90%)
Organ involvement is early in diffuse systemic sclerosis and there is early onset of
pulmonary fibrosis. Pulmonary artery hypertension is common in the limited disease
and has a late onset. Renal crisis is commoner in diffuse systemic sclerosis.
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SCLERODERMA DIAGNOSTIC CRITERIA
The diagnosis for scleroderma is made on the basis of the criteria devised by
American college of rheumatology (ACR) in 1980
Major criteria – symmetric proximal sclerosis extending beyond metacarpal
phalangeal joint and metatarsal joint
Minor criteria – 1) sclerodactyly
2) digital pitted scars/loss of substance over finger pads
3) bibasilar fibrosis
The diagnosis is made on the basis of presence of one major or two or more minor
criteria.
This criterion has a sensitivity of 97% and specificity of 98%. The limitation of this
classification was that patient with early systemic sclerosis and 20% of patients with
limited disease were excluded from diagnosis.(46)
Leroy and Medsger in 2001 modified the earlier ACR criteria to include early
systemic sclerosis. Early scleroderma was diagnosed on the basis of abnormal
capillary findings and presence of auto-antibodies in the absence of cutaneous
features.(47)
Recently, a new classification criteria of systemic sclerosis has been recommended
by the European League against Rheumatism (EULAR) and American College of
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Rheumatology (ACR) which is shown in table 3. According to this criteria skin
thickening of both hands extending proximal to the metacarpo-phalangeal joint is
sufficient for diagnosis of scleroderma. In addition there are 7 items with subsets
having weighted scores. The subset with higher score is taken for calculation of the
total score. A score of > 9 is required for diagnosis. This criterion has a sensitivity of
91% and specificity of 92%.(48)
TABLE 3: EULAR CLASSIFICATION
ITEM SUBSET POINTS
Skin thickening of both hands
extending proximal to the mcp
joint(sufficient criterion)
9
Skin thickening Puffy fingers
Sclerodactyly(distal to MCP joint
and proximal to PIP joint)
2
4
Fingertip lesions Digital tip ulcers
Digital pitted scars
2
3
Telangiectasia 2
Abnormal nail fold capillaries 2
Lung involvement Pulmonary artery hypertension
Interstitial lung disease
2
2
Raynaud’s phenomenon 3
SSc related auto antibodies Anticentromere 3
Antitopoisomerase I
Anti RNA polymerase III
3
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CLINICAL FEATURES
The most commonly involved organ is the skin which is almost always affected and
is considered to be the cardinal feature for diagnosis.  The other organs involved are
lungs, heart, kidneys, gastrointestinal system and heart.(2)
Cutaneous Features
The most commonly involved sites include the hands, face and the lips. In a study
done in Leeds, hands were involved in 95% followed by the chest in 30% and feet in
15%.(4)
Skin sclerosis
The skin over the hands and face are the most commonly involved sites. The stages
in skin involvement include oedematous, indurated and atrophic phases. In the
oedematous phase, there is pitting edema involving the digits with a doughy feel also
called sausage digits. The oedema is attributed due to deposition of dermal
glycosaminoglycan, vascular and hydrostatic changes.(1) It progresses to the
indurated phase or the sclerotic phase where the skin becomes taut and shiny. Rapid
progression from indurated phase to sclerotic phase is associated with bad prognosis
and diffuse involvement. The fingers at this stage are referred to as Madonna’s
fingers.(49) The cutaneous sclerosis typically starts acrally involving the finger tips
and hands but may progress proximally and symmetrically to involve the trunk and
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face. There is associated decreased sweating, loss of hair with loss of skin creases
with inability of skin to fold. It progresses to the final stage, the atrophic stage where
the skin becomes tight and hidebound with loss of subcutaneous tissue and formation
of flexion contractures and digital ulcers. Rapid progression of sclerosis is associated
with bad prognosis whereas gradual progress is associated with a good prognosis.
(49)(4) Skin sclerosis was seen in all patients in a study by Krishnamurthy et al. and
in 98.5% of patients in a study by Sharma et al. The prevalence of skin sclerosis was
86% in the whites and 96% in African American in a study by Reville et al. (8) (50)
(53)
Face involvement
In a well developed case there are characteristic facial features. The skin is bound
down and hard with shiny forehead and loss of expression lines with typical mask
like facies. The nose is small with pinched or beaked appearance. The mouth opening
is decreased with pursed appearance due to radial furrows and thinning of upper lips.
Microstomia can be associated with difficulty in talking and eating. Inter-incisor
distance can be decreased in both the vertical and horizontal direction in
scleroderma.(4) The lower eyelid cannot be everted due to loss of subcutaneous
tissue(Ingram’s sign).(51) Mucosal involvement can present with frenulum
shortening secondary to sclerosis.(52) Rarely, periorbital oedema and mandibular
atrophy have been reported. (53) Chondrodermatitis nodularis helicis was reported in
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3 of 21 patients with limited disease. They present as painful nodules over the helix
of the ear.(54)
Neck sign
The neck sign also referred to as Barnett’s sign is the prominence of the platysma on
hyperextension of the neck and seen in 90% of the patients. It is a useful diagnostic
tool to differentiate from primary Raynaud’s phenomenon and in case of limited or
early scleroderma where clinical features may not be apparent.(55)(56)
Pigmentary disturbances
Pigmentary disturbances are present in 50% of the patients and can present as salt
and pepper pigmentation, depigmentation and diffuse hyperpigmentation.  Patients
presenting with diffuse hyperpigmentation have accentuation in sun exposed areas
and pressure areas.  Salt and pepper pigmentation also referred to as leucoderma of
scleroderma presents as depigmentation with retention of perifollicular pigmentation.
It commonly involves the upper trunk and face, but may also involve uninvolved skin
and sclerotic skin.(1)(4)(52) In a study by Sharma et al. the pigmentary abnormalities
noted were diffuse pigmentation in 88.1%, mottled hypo-depigmentation (salt and
pepper-like pigmentation) in 51.2% and depigmentation at the sites of scars in
31.3%.(8)
The mechanism of pigmentation in scleroderma is not known. Endothelin -1(ET-1)
which is produced in the keratinocytes promotes melanin synthesis and melanocyte
production. Increased ET-1 production in keratinocytes has been correlated with
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pigmentation and can be associated with severe disease.(57) The retained
perifollicular pigmentation is attributed to retainment of melanogenesis in the
perifollicular capillaries.(58)
Telangiectasias
Mat like telangiectasias is present in 75% of the patients and varies in size from 2mm
to 20mm. It is commonly seen in face, mouth, lips, hands and upper trunk. They are
representative of dilated venules and blanch on pressure. It can be present in the
limited and diffuse type of disease.(4)(52) In a study by Sharma et al. the prevalence
was 36.8%, the prevalence in the western population was 51% in the whites and 59%
in the Hispanics.(8)(59)
Calcinosis cutis
Calcinosis cutis is a type of dystrophic calcification which presents as discharging
chalky white discharge over the fingers, hand, elbow, knee, ankle and the iliac crest.
It generally presents late in the disease course. Calcinosis cutis is seen in 25% of the
patients and more commonly affects the females.(4)(52)(60)
Digital ulcers
The ulcers commonly involve the finger tips, but may also involve the ulnar border
of the thumb and radial border of index finger. The digital ulcers may progress to
form gangrene or undergo auto amputation or may resolve with scarring. The scars
are normally present over the finger tip but may also involve the ulnar border of the
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thumb and radial border of index finger.(4)(61) In a study by Sharma et al., the
prevalence of digital ulcers was 58.6% and in a study by Krishnamurthy et al. the
prevalence was 47.4%. The prevalence in the western population was higher (82%)
as studied by Reville et al.(59)
Round finger pad sign
This sign refers to replacement of finger tip contour from peaked to hemisphere like
tip. It is most commonly seen in the ring finger. It can serve as a clinical tool for
early diagnosis of scleroderma. It can also be present in mixed connective tissue
disorder and primary Raynaud’s disease.(62)(63)
Nail changes
The nails curve over the atrophic phalanges and become small with atrophy of distal
portion of the fingers. Other nail changes include ragged cuticle, paronychia, beaking
of nails and pterygium inversum unguis.  Pterygium inversum unguis is not specific
to scleroderma and can be present in other connective tissue diseases.
(4)(64)(65)(66)
Lower limb involvement
In the lower limbs the skin manifestation of scleroderma could be ulcers (40%),
livedo reticularis or atrophie blanche.
Other rare cutaneous findings include hyperkeratotic plaques over the phalanges due
to deposition of amyloid, small papules secondary to lymphangiectasia and lesions
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resembling acrokeratoelastodosis.(67)(68) Rarely, they can be present as
subcutaneous nodules resembling erythema nodosum.(69)(70)
Raynaud’s phenomenon
Scleroderma is one of the commonest causes of secondary Raynaud’s phenomenon.
It is characterised by white, blue and red discoloration of fingers due to episodic
vasospasm of the digital arteries due to cold stimuli. At least two phases are required
for the diagnosis of Raynaud’s phenomenon. It is seen in 90% of patient with diffuse
systemic sclerosis and 99% with limited systemic sclerosis.(49)(71) The prevalence
of  Raynaud’s phenomenon was 92.9%, 100% and 96% in studies by Sharma et al.,
Adhadh et al and Reville et al respectively. (8)(72)(59) Other causes of Raynaud’s
phenomenon include connective tissue disorders like Sjogren’s disease and SLE,
carpal tunnel syndrome, secondary to drugs like bleomycin, frost bite and exposure to
vinyl chloride.(1) Raynaud’s phenomenon represents an imbalance in the
vasodilatation –vasoconstriction cycle favoring vasoconstriction.(73)
ASSESSMENT OF SKIN INVOLVEMENT
1. Rodnan skin scores
It is a semi-quantitative tool which measured 26 sites and weighed the skin
biopsies and collagen content. The modifications include 17, 20 and 22 sites.
(Annexure - III). It is an easy bed side test to assess disease severity and also
is of prognostic value. Increased score is associated with internal organ
involvement. The disadvantage is that it has high intra and inter observer
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variability and does not differentiate between thickening and tightness.
(74)(75)
2. Durometer
It is used to measure the hardness of the skin. Its values correlate with values
of Modified Rodnan Skin Score(MRSS) and ultrasound.(75)(76)(77)
3. Ultrasound
Ten to 30 hertz ultrasound are useful in assessment of skin thickness. Dermal
thickness is more accurately measured with 20 to 30 hertz. It produces good
results with minimal intra and inter-observer variability. The disadvantage is
the time constraints.(75)(77)
4. Plicometer
It measures the thickness of folded skin (plica) but is yet to be validated. It is
more sensitive and specific than mRSS and can be used for follow up of
patients.
5. Magnetic Resonance Imaging - skin
It measures skin thickness with musculoskeletal involvement along with
calcinosis. The disadvantage is that it is expensive.
6. Skin biopsy
The degree of sclerosis can be assessed by measuring the collagen content
and the dermal thickness. Hydroxyproline content can also be correlated with
skin scores.
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7. Others
Twistometer, cutometer, elastometer(77)
Extracutaneous involvement
Respiratory system
Respiratory involvement is the leading cause of death in patients with systemic
sclerosis. It may manifest as pulmonary artery hypertension or interstitial lung
disease. Pulmonary artery hypertension though present in both types, is more typical
for the limited type. It is of prognostic significance and early initiation of therapy
improves survival.(4) In a study by Sharma et al., the prevalence was 51% and in a
study by Pradhan et al. it was 77.3%.(8)(12) In a study conducted in Thailand by
Ruangjutipopan et al. and in Iraq by Adhadh et al. the prevalence was 57.4% and
32% respectively.(78)(72)
Renal system
Renal involvement is the commonest cause of acute mortality and has one of the
worst prognosis among the internal organ involvement. Acute renal crisis is the
greatest risk in patients with rapidly progressing diffuse type of systemic sclerosis
and they present with malignant arterial hypertension, cramps, visual disturbances
and left ventricular hypertrophy. These patients benefit from early initiation of
Angiotensin Converting Enzyme inhibitors(ACEI) and regular monitoring of blood
pressure.(4)(52) The prevalence of renal involvement was 6% and 10.9% in two
studies from India.(8)(12) A study in Thailand by Ruangjutipopan et al. and Iraq by
27
Adhadh et al. showed renal involvement in 5.8% and 9% of their study
population.(78)(72)
Cardiovascular involvement
Cardiovascular involvement can present with pericardial or myocardial involvement
and conduction abnormalities. It can also be secondary to the kidney and lung
involvement. Pericardial effusion is generally asymptomatic. Conduction
abnormalities are complete heart block, atrial tachycardia, atrial fibrillation and
ventricular tachycardia. The most serious complication is myocardiopathy which
presents with cardiac fibrosis and rapidly progressive myocardial failure.(4) In a
study by Pradhan et al, the cardiovascular involvement was seen in 13.6% of patients.
(12)
Gastrointestinal involvement
Gastrointestinal system is a common internal organ involvement. It presents with
gatroesophageal reflux and distal dysphagia. Chronic oesophagitis may be associated
with ulceration and stricture formation. The involvement of the stomach may result
in delayed peristalsis with dilatation and delayed gastric emptying. Gastric antral
vascular ectasia is seen in the diffuse type of systemic sclerosis and is referred to as
watermelon stomach due to its endoscopic appearance. The duodenum involvement
results in postprandial bloating, abdominal pain and regurgitation. The intestinal
involvement presents with recurrent pseudo obstruction or malabsorption. Rarely,
mega colon, rectal prolapse or colonic diverticula may be present.  Primary biliary
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cirrhosis can also be associated.(1)(4) In a study by Sharma et al, the prevalence of
GI involvement was 70.2% and in a study by Pradhan et al. it was 7.3%.(8)(12) The
prevalence of GI involvement was 41.9% in studies from Thailand and Iraq.(78)(72)
Musculoskeletal involvement
Systemic sclerosis is the only condition where phalangeal absorption is associated
with calcinosis. In 70% of the cases the phalangeal absorption is mild and affects
only one terminal phalange. It can also involve the middle and proximal phalanges
and develop erosive arthropathy involving the distal inter-phalangeal joint similar to
psoriatic arthropathy. Resorption of the zygomatic arches and mandible can present
with pain in the temporomandibular joint and grinding sensation on chewing.
Osteolysis can also affect the shoulder joint, ribs, cervical spine, radius and ulnar
bones. Rarer associations include intraosseous deposition of calcium, avascular
necrosis of femoral head and osteopoikolosis which is characterized by islands of
bone in the epiphysis and the metaphysis. In some cases carpal tunnel syndrome may
be the presenting complaint. The involvement of juxta-articular tendons can lead to
fibrosis and result in friction rub.
Myopathy can present in two ways, inflammatory and the non- inflammatory type.
The non inflammatory type is commoner and present in 60 to 80% of the patients and
presents with minimal elevation of CPK with mild weakness. The inflammatory type
simulates polymyositis and is characterised by elevated CPK and aldolase levels and
positivity for PM-Scl antibodies.(4)(52)
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Dental involvement
Periodontal widening can be secondary to fibrosis and thickening of the vessel wall .
Stafne’s sign refers to widening of periodontal ligament space. It occurs in 30% of
the patients and can affect the entire root, anterior and posterior teeth and lamina
dura. It can also lead to osteolysis of the coronoid process and mandibular angle
leading to loss of teeth.(52)
Neurological involvement
Neurological involvement is rare and affects less than 10% of the patients.  It can
present as trigeminal neuralgia which initially presents unilaterally which may
progress to become bilateral.  Other neurological manifestations include peripheral
neuropathy, carpal tunnel syndrome, meralgia paraesthetica and spinal cord
compression secondary to calcification. Sub acute combined degeneration of spinal
cord can be secondary to vitamin B12 deficiency.(4)(52)
Eyes
Decreased tear secretion, keratoconjunctivitis sicca, tightness of eyelids with shallow
fornices are specific eye changes. Vascular involvement can lead to retinopathy with
central retinal vein involvement.(79)(80)
Others
Sjogren’s syndrome can be seen in 15% of the patients. Impotence and
hypothyroidism secondary to thyroid fibrosis have also been reported. It can also
present with overlap features of other connective tissue disease.(4)
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AUTOANTIBODIES ASSOCIATED WITH SYSTEMIC SCLEROSIS
The investigations are broadly divided as investigations to confirm diagnosis and
assessment of systemic involvement. Auto antibodies testing are useful in confirming
the diagnosis. Antinuclear antibody (ANA) positivity is present in 78% and 97% with
rat liver and Hep-2 cells. The common patterns include speckled, homogenous and
nuclelolar with nucleolar and discrete speckled being specific for systemic sclerosis.
Antibodies to topoisomerase I (Scl-70) causes diffuse frost staining of nuclei is seen
in 20% of the patients and is associated with diffuse disease with increased risk for
interstitial lung disease.(81) Anticentromere antibodies are associated with the
limited type.  Anti RNP antibodies is associated with risk of diffuse type of disease
and renal involvement. Anti Sm antibodies are also associated with renal
involvement. Other autoantibodies which are associated include antifibrillarin
antibodies(associated with diffuse type), anti PM-Scl(associated with
dermatomyositis overlap) and anti SSA (associated with sjogren’s disease) as
mentioned in table 2.
DIAGNOSTIC TESTS
Other serological abnormalities include anemia, elevated ESR (approximately 50%)
and false positive VDRL in 5% of patients. There can be associated cold agglutinin
positivity and cryoglobulinemia. Rheumatoid Factor is positive in 30% of the
patients. The investigations which are done to evaluate systemic involvement include
chest X-ray, electrocardiogram (ECG), echocardiogram, barium swallow and renal
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function tests. Skin biopsy shows fibrosis of the lower dermis and subcutaneous
tissue with sparse adnexa with perivascular sparse lymphocytic infiltrate.(4)
In a study by Sharma et al ANA positivity was present in 89.1% with commonest
subtype being speckled in 62.1%.(8) The prevalence of ANA positivity was 85.5% ,
scl-70 was 62.7% and anticentromere antibodies was 22.7% in the study by Pradhan
et al.(12)
ASSESSMENT OF VASCULAR INVOLVEMENT
The clinical manifestations of vascular involvement of scleroderma are diverse and
include Raynaud’s phenomenon, digital ulcers and pulmonary arterial hypertension.
(82). The changes involve the microcirculation as well as arterioles. The assessment
of the vascular involvement include clinical parameters , non invasive techniques and
detection of circulatory markers.(83)
CLINICAL PARAMETERS
1) Raynaud’s Phenomenon
The propensity of vasospasm is best demonstrated by Raynaud’s phenomenon.
Attacks of Raynaud’s phenomenon are assessed by the involved digits,
frequency, and symmetry, severity of symptoms and assessment of pain.
Raynaud’s Condition Score (RCS) combines visual analogue score with
frequency and duration of attacks.
32
2) Digital Ischemia
Digital ischemia is assessed by finger tip ulcerations which resolve with
scarring and gangrene involving the fingers. It is important to note the digital
scars (active/ pitted), atrophy of digital pads and digital amputations.
3) Telangiectasias
Telangiectasias are dilated small blood vessels which are visible to the naked
eye and are representative of dilated capillaries and venules. They are
commonly seen in the limited type of disease.
NON INVASIVE TECHNIQUES
The non-invasive techniques for assessing vascular involvement include functional
assessment, digital blood pressure, skin temperature, digital vascular response to
endothelial dependent and independent dilators, nail fold capillary examination,
transcutaneous oxygen pressure and exercise performance.
1) Functional assessment
Functional assessment includes Doppler studies and provocative tests.
Doppler studies assesses blood flow in the vessels by measuring the velocity,
waveform, wall lumen ratio and digital pressure. The flow patterns should be
assessed in the digital radial arch, palmar and digital arteries. Studies have
showed that there is a decrease in all parameters in primary and secondary
Raynaud’s phenomenon but it is difficult to differentiate between the two
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types. Provocative tests include cold challenge and assessment of vasodilatory
capacity.
(i) Cold challenge test
This test is performed by exposure of finger to cold or whole body cooling
using a cooling blanket in a temperature controlled room. The circulatory
adequacy is assessed by measurement of digital pressure, skin temperature and
flow studies every 5 minutes till it returns to normal temperature. If it is
prolonged for more than 20 minutes it is considered to be positive for
Raynaud’s phenomenon. This test does not distinguish primary from
secondary Raynaud’s phenomenon.
(ii) Assessment of vasodilatory capacity
Hyperemia is measured after heating the body up to 43°C and assessing flow
using Doppler studies. In systemic sclerosis, maximum vasodilatation is
inversely related to number of affected internal organs. (83)
(2) Digital Blood Pressure
Reduction in digital blood pressure by >70% after cooling helps in differentiating
Raynaud’s phenomenon secondary to systemic sclerosis from primary Raynaud’s
phenomenon and has 97%  sensitivity and zero digital pressure at 30°C has 100%
specificity.
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(3) Skin Temperature
Skin temperature and digital pressure should be measured in a controlled
environment. These parameters correlate inversely to digital ulcer healing time. (83)
CIRCULATING VASCULAR MARKERS
Vascular markers are cells that get detached from blood vessels which is indicative of
vascular injury. It correlates with direct endothelial injury.The various markers which
aid in the assessment of vascular involvement include:
(i) Soluble adhesion molecules: E –selectin, P-selectin, ICAM, VCAM - involve
the involved and uninvolved skin. E and P selectin are associated with early
disease and lung fibrosis. ICAM is associated with digital infarcts and VCAM
is associated with elevated ESR and cardiac involvement.
(ii) Endothelin -1 levels
(iii) Nitric oxide
(iv) Prostacyclin
(v) Thrombomodulin
(vi) Anticentromere antibodies
(vii) Von willebrand factor
(viii) Antiendothelial cell antibodies
(ix) Angiotensin converting enzyme (ACE) levels
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DERMOSCOPY
Dermoscopy helps in viewing morphological features which are not seen by the
naked eye and serves as a link between morphological features and pathology.(84) In
scleroderma its use is based on the principle that systemic vasculopathy affects
the nail fold vascular configuration which leads to capillary loss, dilated and
giant capillaries.(85)
History
It was first described in 1663 by Johan Christophorous when he described nail
fold capillaries using a microscope. It was later described by the Italian
Physician, Giovanni Rasori where he described a relationship between dilated
capillary loops and conjunctival inflammation. Brown and O’Leary were the first
people to describe the micro vascular abnormalities during Raynaud’s
phenomenon.(86)
Classification
Nail fold capillary changes are classified into normal pattern, scleroderma pattern
and non specific type by Cutolo et al.(3)(87)
(a) Normal pattern - homogenous capillary distribution without capillary loss in
the nail plexus (30 capillaries/5mm).
(b) Scleroderma pattern - divided into 3 types based on classification by Maricq
et al and Bergman et al. It is said to be scleroderma pattern if it has two or more
abnormalities.
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i) Early pattern – The early pattern has relatively preserved capillary
architecture with no obvious capillary loss and few enlarged or giant
capillaries with few capillary hemorrhages.
ii) Active pattern –There is moderate capillary loss with frequent giant
capillaries and capillary hemorrhages.
iii) Late pattern –There is severe capillary disorganisation with severe
loss of capillaries with large avascular areas. There are frequent ramified or
bushy capillaries.
Non specific type - The capillary changes don’t have the complete scleroderma
pattern
Nail fold capillaries were classified by the German study group (88)(89) as :
Stage I (ectasia) – normal capillaries with possible edema, capillary ectasia
and bleeding
Stage II (individual megacapillaries) – ramification of capillaries,
increasing oedema, increase in ectatic capillaries and mega
capillaries
Stage III (predominantly megacaillaries) – decreased density, increased
megacapillaries, increased oedema and deformity
Stage IV (scar) – severe oedema and avascular areas, few deformed
capillaries
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An absolute marker for scleroderma capillary pattern is giant capillaries with
homogenous enlargement (diameter>50μm).(73) Giant capillaries are
representative of abnormal angiogenic response to peripheral ischemia. Capillary
haemorrhages are representative of Raynaud’s phenomenon and multiple are
more in favour of scleroderma. Avascular pattern is indicative of severe
peripheral ischemia.(3)
Role of Dermoscopy in Systemic Sclerosis
1. It is useful in differentiating between primary and secondary Raynaud’s
phenomenon. Early detection of abnormal capillaries by dermoscopy
maybe of significance with the advent of new drugs which affect vascular
remodeling like ACEIs, endothelin receptor antagonists and
prostanoids.(73)
2. It can also be used to predict the risk of developing systemic sclerosis
based on capillary findings and Raynaud’s phenomenon especially in the
limited subtype of disease(68)
3. It is also useful as it may be the initial indicator of digital micro vascular
injury and can be a useful tool for follow up.(87)(73)
4. Studies have shown vascular remodeling improves with addition of
immunosuppressant, hence nail fold dermoscopy can be used as tool to
assess response to treatment.(84)
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Diagnosis of Early Scleroderma
Studies have shown that in children with Raynaud’s phenomenon capillary
changes occur 6 month prior to the onset of the disease suggesting a strong
correlation between Raynaud’s phenomenon and nail fold capillaries
Significance of various nail fold dermoscopic findings
1. Enlarged/giant capillaries –abnormal angiogenic response secondary to
peripheral ischemia
2. Capillary haemorrhage – These are considered to be secondary to ischemia
and reperfusion. Single haemorrhage can be present in normal individuals.
Multiple haemorrhages are seen in scleroderma and dermatomyositis
3. Avascular areas – indicative of severe peripheral ischemia and increased
probability of developing digital ulcers.
4. Bushy capillaries – These are present in hypovascular areas and are
representative of abnormal angiogenic response (3)
Dermoscopic patterns in other connective tissue disorders
(a) Dermatomyositis – disorganised capillary architecture with bushy
capillaries, less frequently capillary haemorrhages with giant capillaries
may be seen
(b) Systemic lupus erythematosus - disorganised capillary architecture with
dilated capillaries.
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(c) Anti phospholipid syndrome – capillary microhaemorrhages are present
(d) Sjogren’s syndrome – confluent capillary haemorrhages and pericapillary
haemorrhages(86)
In a study done in Turkey showed that 83% of the scleroderma patients had nail
fold capillary changes. The most common pattern was dilated capillary loops
(47%) followed by giant capillaries(34%) and normal capillary configuration
(17%). No difference was noted in capillary configuration in limited and diffuse
systemic systemic sclerosis. Decreased number of capillary loops can also be
predictive for extensive skin involvement and 49% had digital trophic lesions.
(90)
Beltran et al. studied capillaroscopic features in 56 patients with Raynaud’s
phenomenon. Normal capillaroscopy was revealed in all patients with primary
Raynaud’s disease and 11 of 12 patients with pre scleroderma. Scleroderma
pattern was observed in 73% of patients with limited disease and 82% of patients
with diffuse disease. Avascular areas correlated with severe Raynaud’s
phenomenon, bone resorption and diffuse type of disease.(87)
A recent study by Hudson et al. also examined the reliability of dermoscopy in
assessing nail fold capillary abnormalities. These investigators assessed inter- and
intra-observer reliability in identifying the presence or absence of three specific
features—dilated loops, giant capillary loops and avascular areas. Four fingers in
each of six patients with systemic sclerosis and two controls were examined. For the
40
three features, the k-coefficients for inter-observer variability were 0.63 (dilated
loops), 0.40 (giant capillaries) and 0.20 (avascularity), and for intra-observer
variability 0.71, 0.55 and 0.40, the authors concluded that reliability for dilated and
giant capillaries was good and that dermoscopy was therefore a useful tool.(91)
Ong et al. studied 20 patient with limited type of disease and concluded that
patient with pulmonary artery hypertension had lower capillary density.(92) Hoftstee
et al concluded that severity in pulmonary artery hypertension correlated with the nail
fold density. The study did not find any correlation with other co-morbidities. (93)
Dermoscopy is a useful non invasive tool that differentiates between primary and
secondary Raynaud’s phenomenon. It is also useful in the early diagnosis as well as
staging of the disease. It is a useful tool for prognostication and follow up. In
conclusion it is a useful diagnostic tool and can serve as an indicator of internal organ
involvement. (94)
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MATERIALS AND METHODS
Study design
Hospital based cross-sectional study of all the patients with systemic sclerosis
Setting
The study was conducted in the Dermatology, Venereology and Leprosy Unit -2
OPD and the Rheumatology Out-patient Clinic and ward.
Study Duration
The study was conducted from February 2014 to September 2015(20 months)
Inclusion criteria
o Patient with diffuse systemic sclerosis  who fulfill ACR criteria
o Patient with limited systemic sclerosis with  sclerosis involving the
hands and feet and are positive for anti-CENP antibodies
o Age > 16 years
o Patients who are willing to take part in the study
Exclusion criteria
o Patients with overlap with other connective tissue disorders
o Patients who do not wish to be included in the study
42
Inclusion criteria for measurement of interleukin 6 levels
 Patients with diffuse systemic sclerosis who fulfill ACR criteria and are
positive for anti scl-70 antibodies
 Patients who are willing to take part in the study
Exclusion criteria for measurement of interleukin 6 levels
 Patient with limited systemic sclerosis
 Fever with active infection
 Associated malignancy
METHODOLOGY
Patients who fulfilled the inclusion criteria were enrolled in the study. The diagnosis
of diffuse scleroderma were based on the American College of Rheumatology (ACR)
criteria (Annexure -I) and the diagnosis of limited type was based on the presence of
sclerodactyly and positivity for anti-CENP antibodies. All the patients and/or the
guardians were informed about the purpose of the study and informed consent was
obtained (Annexure –II ).
All the patients were examined by the principal investigator and the details obtained
from the patient or legal guardians were entered in a proforma (Annexure –III). The
details were collected and subsequently entered in an electronic database.
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Demographic details
Socio-demographic data including the age at recruitment into the study, gender, place
of stay and duration of the disease were recorded.
History pertaining to the disease
1. Presenting cutaneous complaints( Raynaud’s phenomenon, skin sclerosis) and
duration of the same were recorded
2. Systemic complaints (gastrointestinal, respiratory, cardiac, renal,
musculoskeletal) were recorded
3. Past history of skin lesions and treatment history including topical and
systemic medications were recorded
Clinical examination
All patients were examined for the presence of any cutaneous manifestations of
systemic sclerosis and a record of the morphology and distribution of the lesions
were made.
The cutaneous features we looked for included -
Face;- radial furrows, beaked nose, inability to evert lower eyelid, smoothening of
forehead expression, mouth opening, periorbital oedema and mask like facies
The cut off values for restricted mouth opening used in our study was 43mm in
males and 37.6mm in females
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Upper limbs;- digital ulcers, digital scars, pitting edema of fingers, sclerodactyly,
gangrene, round finger pad sign, flexion contracture and cobblestone appearance.
Round finger pad sign refers to replacement of finger tip contour from peaked to
hemisphere like tips.
Nails;- dystrophic nails, ragged cuticles, resorption of phalanges, pterygium inversum
unguis
Lower limb;- leg ulcers, atrophie blanche and livedo reticularis
Other features looked for includes;-calcinosis, telangiectasias, pigmentary
disturbances and presence of neck sign. Neck sign refers to the prominence of
platysma on hyperextension of neck.
The extent and site of involvement of cutaneous sclerosis was noted in all patients.
Modified Rodnan skin score(Annexure - III) was calculated to assess severity of
disease for each patient at the time of first contact of the patient with the primary
investigator.
Dermoscopy of the nail fold capillaries was performed using a Heine delta 20
dermoscope by examining all the finger nail folds after immersion with ultrasound
gel. The most common nail fold capillary finding found among all digits was taken
for analysis. The combination of abnormal findings seen in nail fold were also noted
The abnormal capillary findings looked for included dilated capillaries, drop out,
avascular pattern , giant capillaries and capillary haemorrhages. Capillary dilation
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refers to enlargement of capillary lumen. Capillary drop out refers to focal areas of
capillary loss and avascular areas to refers to multifocal or diffuse loss of
capillaries.(89)Capillary haemorrhages refers to dotted or lined microhaemorrhage
was located at periphery of capillaries. The capillary findings were classified on the
basis of the classification devised by Cutolo et al. and Maricq et al. into normal
pattern, scleroderma pattern and non specific type. (3) (87) (95)
(a) Normal pattern - homogenous capillary distribution without capillary loss in
the nail plexus
(b) Scleroderma pattern - divided into 3 types based on classification by Maricq
et al and Bergman et al.(96) (97) It is scleroderma pattern if it has two or more
abnormalities.
i) early pattern – The early pattern has relatively preserved capillary architecture
with no obvious capillary loss. There are few enlarged or giant capillaries with
few capillary hemorrhages.
ii) Active pattern – There is moderate capillary loss with frequent giant
capillaries and capillary hemorrhages.
iii) Late pattern – There is severe capillary disorganisation with severe loss of
capillaries with large avascular areas. There are frequent ramified or bushy
capillaries.
(c)Non specific type - The capillary changes don’t have the complete
scleroderma pattern
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Clinical photographs were taken using Sony Cybershot DSC-H55 camera. The
diagrammatic algorithm of the study is shown in figure -4.
FIGURE 4 – DIAGRAMMATIC ALGORITHM OF THE STUDY
Investigations
1. Serology - ANA, anti topoisomerase and anti centromere antibodies were
recorded
2. HRCT chest and abdomen
Patient from dermatology OPD / inpatient
who fulfill inclusion criteria
Patient from rheumatology OPD /
inpatient who fulfill inclusion criteria
Clinical Details, Cutaneous examination,
Nail fold dermoscopy performed
Modified Rodnan skin score (20 site)
calculated
Patient with diffuse systemic sclerosis
Serum IL-6 measured
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3. Interleukin -6 - A blood sample was collected for measurement of serum
interleukin 6 levels in a subset of patients with diffuse systemic sclerosis who
were SCl-70 positive. Interleukin 6 levels were quantitated in the serum by the
commercial available ELISA kit following manufacturer’s protocol. ELISA
was performed in duplicates i.e each samples was run in two wells and
average was taken. Results were expressed as pg/ml and were treated as
continuous variable.
The other investigations like ECHO and barium swallow were done when
indicated.
Sample Size
The sample size was calculated based on the study by Dogan et al.
The sample size was calculated presuming the frequency of nail fold
dermoscopy finding as 50% and the sample size was calculated using the
formula
N = 4pq
----------
d²
p - 50                q - 50                     d -10
4 x 50 x 50
N= --------------- = 100
10x10
Statistical Methods
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The prevalence was expressed in terms of percentages along with 95% confidence
intervals. The prevalence of the various cutaneous lesions in scleroderma was
expressed as numbers and percentages. The association of dermoscopic capillary
pattern and rodnan skin score with various clinical manifestations was evaluated
using χ² tests. Epiinfo (version 7), a data management software was used for the data
entry. SPSSPC version 21 was used for analysis.
Study Approval
This study was approved by the Institution Review Board (IRB No - 8594[observe])
(Annexure - 7)
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RESULTS
DEMOGRAPHIC PROFILE
Thirty five patients with the diagnosis of scleroderma were included in the study
between February 2014 and September 2015. The characteristics of the study
population have been described below.
AGE DISTRIBUTION
Age of the patients included in the study ranged from 17 and 62 years. The
mean age was 36.29+ 12 years and the median age 36 years. In the study population
63% were between 20 and 39 years of age. The age distribution of the patients is
shown in figure -5.
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SEX DISTRIBUTION
Out of the 35 patients included in the study, there was a female predominance with
30 (86%) females and 5 (14%) males in the study as shown in figure 6. The male to
female ratio was 1:6.
Figure 7 shows the age and sex distribution of the study population. Females
outnumbered males in all the age groups.  The majority of the females were present
in the 30-39 age group (33.3%) followed by 20 – 29 (30%) age group. Of the 5 males
in the study, 2 each (40%) were in the 20 -29 and 40-49 age group and one male was
in the 30 to 39 years age group.  There were no males below the age of 20 and above
the age of 50 years.
MALE
14%
FIGURE 6: SEX DISTRIBUTION
FEMALE
86%
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FIGURE 7 – AGE SEX DISTRIBUTION
GEOGRAPHICAL DISTRIBUTION
West Bengal accounted for 40% of the patients in the study followed by 6(17.1%)
from Tamil Nadu and 5(14.3%) from Jharkhand. There were 2 patients from
Bangladesh. Most of the cases were from the Eastern region of India contributing
68% of the study population as shown in figure 8.
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FIGURE 8 – GEOGRAPHICAL DISTRIBUTION
DISEASE CHARACTERISTICS
TYPE OF DISEASE
Scleroderma patients were classified into diffuse and limited based on the clinical
and immunological characteristics. Majority (91%, n=32) of the patients had diffuse
type of disease and only 9 %( n=3) had limited disease as shown in figure 9.
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DURATION OF DISEASE
The mean duration of disease in the study population was 43.31+ 31.8  months and
the median was 36 months. The  duration of the illness ranged from 4 to 120 months.
There was a high proportion of patients with disease duration more than 5 years at
the time of presentation (37.1%) as shown in table 4. This can be explained as most
patients had initially presented in other settings prior to coming to our centre.
TABLE 4 : DURATION OF DISEASE
Duration of illness
(months)
Frequency percentage
< 12 4 11.4
12-23 6 17.1
24-35 7 20
36-47 3 8.6
48-59 2 5.7
>= 60 13 37.1
FIGURE 9 - EXTENT OF DISEASE
DIFFUSE
91%
LIMITED
9%
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PRIOR TREATMENT RECEIVED
Duration of treatment among our study population is depicted in table 5.Among the
35 patients studied, 11 patients were treatment naïve. Among the 24 patients who
had received prior treatment, the mean duration of treatment was 16.33+ 15.1
months with the median duration being 9 months. The duration ranged from 1 to 48
months.
TABLE 5 - DURATION OF TREATMENT
Duration of treatment(months) Frequency Percentage
< 12 13 54.2%
12-23 3 12.5%
24-35 2 8.3
36-47 4 16.7%
48 and above 2 8.3%
The majority of patients were treated with systemic steroids either as prednisolone or
deflazacort tablets or dexamethasone cyclophosphamide pulse therapy. Other
immunosupressants that were commonly used were methotrexate and azathioprine
Other drugs used included hydroxychloroquine and oral PUVAsol.
RAYNAUD’S PHENOMENON AND SKIN SCLEROSIS
The mean duration of Raynaud’s phenomenon and skin sclerosis is shown in table 6
and figure 10 . The mean duration of Raynaud’s phenomenon was 33.6+23.4 months
and the median duration was 24 months. The duration ranged from 3 to 72 months.
Four patients had onset of Raynaud’s within one year of onset of disease. Of the 10
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patients who did not present with Raynaud’s phenomenon, 8 had diffuse systemic
sclerosis and 2 had limited disease. The mean duration of skin sclerosis was 42.19+
34.03 months and the median was 29 months with duration ranging from 3 to 120
months. The duration of skin sclerosis was unknown in 4 patients. In our study
population nine patients presented simultaneously with Raynaud’s phenomenon and
skin sclerosis.
TABLE 6 - DURATION OF RAYNAUD'S PHENOMENON AND SKIN
SCLEROSIS
Duration in
months
Raynaud’s phenomenon Sclerosis
Frequency % Frequency %
< 12 4 16 5 14.2
12-23 7 28 6 17.1
24-35 3 12 5 14.2
36-47 2 8 2 5.7
48-59 2 8 2 5.7
>= 60 7 28 11 31.4
Unknown
duration
4 11.4
Total 25 35
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CUTANEOUS MANIFESTATIONS
All the patients had cutaneous manifestations. Among the 35 patients, 30 had upper
limb involvement and 3 had lower limb involvement. Facial involvement was present
in 27 patients.
Table 7 depicts the cutaneous manifestations on the face. The commonest facial
involvement was beaked nose which was present in 27 patients (77%) followed by
radial furrows(71.4%). An inability to evert lower eyelid was present in 25 patients
(71%). Mask like facies was present in 40% of our patients and only one patient
presented with periorbital oedema. Mat like telangiectasia was present in 10 patients,
most common site being the cheeks. All the patients with mat like telangiectasias had
diffuse systemic sclerosis.
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TABLE 7 –CUTANEOUS MANIFESTATIONS - FACE
Clinical features Frequency Percentage
Beaked nose 27 77.1
Radial furrow 25 71.4
Inability to evert lower eyelid 25 71.4
Smoothening of forehead expression 18 51.4
Mask like facies 14 40
Peri- orbital edema 1 2.9
The mouth opening measurement in our study population is depicted in table- 8. The
mean mouth opening which was measured as inter incisor distance was 43.97 mm
and the median 42 mm. The minimum was 20 mm and the maximum 64 mm.
Reduced mouth opening was present in 54.3% (n=19) of our study population. The
normal mouth opening in an Indian population was 51.3+8.3mm in males and
44.3+6.7 in females. The cut off values used in our study was 43mm in males and
37.6mm in females. (98)
TABLE 8 - MOUTH OPENING
MOUTH OPENING (mm) Number Percentage
< 30 8 22.9
30-39 9 25.7
40-49 7 20
50-59 2 5.7
>= 60 9 25.7
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The cutaneous manifestations in the upper and lower limbs are shown in table 9. The
commonest cutaneous manifestation in the fingers were sclerodactyly (85.7%)
followed by digital pitted scars (51.4%).  Digital ulcers and gangrene of the fingers
were seen only in one patient each. In the study population, 7 patients had flexion
contractures with fingers being involved in 3 patients and the elbows and hands being
involved in 2 patients each. Round finger pad sign was seen in 9 patients. The
commonest site of round finger pad sign was ring finger (55.6%) followed by the
index and middle finger. The commonest manifestation in the nail was ragged
cuticles (65.7%) followed by pterygium inversum unguis (17.1%). Apart from skin
sclerosis, the lower limbs were involved in 4 cases with either leg ulcers or atrophie
blanche.
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Table 9–SKIN LESIONS OF UPPER LIMB AND LOWER LIMBs
Clinical Features Frequency Percentage
Digital ulcer 1 2.9
Digital scar 18 51.4
Pitting edema fingers 2 5.7
Round finger pad sign
Ring finger
Middle finger
Index finger
9
5
2
2
25.7
Flexion contractures
Fingers
Elbow
Hand
7
3
2
2
20
Sclerodactyly 30 85.7
Gangrene 1 2.9
Cobblestone appearance 1 2.9
Nails
Dystrophic nails 4 11.4
Ragged cuticles 23 65.7
Resorption of phalanges 5 14.3
Pterygium inversum unguis 6 17.1
Lower limb
Leg ulcer 3 8.6
Atrophie blanche 1 2.9
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PIGMENTARY DISTURBANCES
Pigmentary disturbances were noted in 33 subjects (94.3%). Hyperpigmentation was
seen in 27 subjects, salt and pepper pigmentation in 23 and depigmentation in 17.
There were 17 subjects with only one pigmentary disturbance, 9 subjects with 2
pigmentary abnormalities and 7 subjects with all three abnormalities. Table -10
shows the frequency of the various pigmentary disturbances.
TABLE 10 –TYPE OF PIGMENTARY DISTURBANCE
Pigmentation Frequency Percentage
Salt and Pepper pigmentation 23 65.7
Depigmentation 17 48.6
Hyperpigmentation 16 45.7
Table-11 shows the distribution of the pigmentary disturbances. Hyperpigmentation
was commonest in the upper limb (37%) followed by the face (22.2%). Generalised
hyperpigmentation was present in 3 patients. Salt and pepper pigmentation was most
commonly present in the trunk (16.98%) and back (16.98%). Three patients had salt
and pepper pigmentation in the retro-auricular region. The face (27.6%) was the
commonest site of involvement for depigmentation.
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TABLE 11 – SITE OF PIGMENTARY DISTURBANCES
Site Depigme
ntation(n
o.)
% Hyperpigmentation
(no.)
% Salt and pepper
pigmentation
%
Generalized - 3 11.1 -
Neck 4 13.8 2 7.4 6 11.3
Upper limb 5 17.2 10 37 10 18.87
Face 8 27.6 6 22 6 11.3
Back 2 6.9 - 9 9 16.98
Ear 3 10.3 - 1 1.89
Lower limb 3 10.3 3 11.1 1 1.89
Trunk 4 13.8 3 11.1 9 16.98
retroauricular - - 3 5.66
Scalp - - 8 15.1
SKIN SCLEROSIS
Site of skin sclerosis and modified Rodnan skin scores are shown in table 12 and 13.
Cutaneous sclerosis was present in 97.1% of the patients. The commonest site of
cutaneous sclerosis was the upper limb (n=34) followed by lower limb (n=19) and
face (n=18).
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Table 12 - SITE OF SCLEROSIS
Site Frequency Percentage
Face 18 52.9
Upper limb 3 100
Chest 10 29.4
Abdomen 4 11.8
Lower limb 19 55.9
MODIFIED RODNAN SKIN SCORE
Skin sclerosis was assessed using the modified Rodnan skin score. The modified
Rodnan skin score ranged from 0 to 48. The mean score was 16.66+ 10.9 and the
median was 15.
TABLE 13 – MODIFIED RODNAN SKIN SCORE
RODNAN SKIN
SCORE
Frequency Percentage
< 10 14 40
10-19 9 25.7
>=20 12 34.3
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Calcinosis was present in only 3 patients with diffuse disease. Neck sign was present
in 20 patients (57.1%). Cobblestone appearance over the neck was present in one
patient(2.9%). Other cutaneous manifestations were seen in 3 patients. These
included melanonychia, melasma and scarring alopecia with depigmentation over the
scalp in one patient each.
COMPARISONS BETWEEN LIMITED AND DIFFUSE SYSTEMIC SCLEROSIS
The clinical manifestations in diffuse and limited systemic sclerosis are compared in
table 14. In diffuse systemic sclerosis beaked nose, radial furrows and inability to
evert eyelid were the commonest cutaneous manifestations. In the limited type of
disease facial involvement was present in only one patient who had beaked nose,
radial furrows and inability to evert eyelid. The only upper limb manifestation in
limited disease is sclerodactyly which was present in all the patients. The nail
involvement of limited disease was ragged cuticles seen in one patient. Lower limb
involvement, neck signs, calcinosis and telangiectasia were absent in the limited
sclerosis group.
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TABLE 14 – CUTANEOUS MANIFESTATIONS – DIFFUSE AND LIMITED
Features Diffuse (n=32) Limited (n=3)
Number percentage Number Percentage
Face
Radial Furrows 24 75 1 33.3
Beaked nose 26 81.3 1 33.3
Inability to evert eyelid 25 78.1 1 33.3
Smoothening of forehead
expression
18 56.3 0
Mask like facies 14 43.8 0
Peri-orbital edema 1 3.1 0
Extremities
Digital ulcer 1 3.1 0
Digital pitted scars 18 56.3 0
Pitting edema of fingers 2 6.3 0
Round finger pad sign 9 28.1 0
Flexion contractures 7 21.9 0
Sclerodactyly 27 84.4 3 100
Gangrene 1 3.1 0
Nails
Dystrophic nails 4 12.5 0
Ragged cuticles 22 68.8 1 33.3
Resorption of phalanges 5 15.6 0
Pterygiuminversum unguis 6 18.8 0
Cobblestone appearance 1 3.1 0
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SYSTEMIC MANIFESTATIONS
The systemic manifestation in systemic sclerosis in our study population is depicted
in table 15. The commonest affected internal organ was lung which presented with
interstitial lung disease in 78.1% of the patients. The second commonest involved
system was the gastrointestinal system which presented as oesophageal reflux in
46.9% followed by oesophageal dysmotility in 28.1%.  The cardiac involvement
included ventricular premature complexes, mitral and tricuspid regurgitation and
anterior wall myocardial infarction.  One patient presented with proteinuria. Myositis
was present in 4 patients .None of the patients with limited scleroderma had systemic
manifestations. Other systemic manifestations include hypothyroidism in 2 patients
and osteoporosis in 2 patients.
TABLE 15 – SYSTEMIC MANIFESTATIONS
Features Diffuse (n=32)
Frequency %
Oesophageal dysmotility 9 28.1
Oesophageal reflux 15 46.9
Interstitial lung disease 25 78.1
Pulmonary artery hypertension 1 3.1
Cardiac 5 15.6
Renal 1 3.1
Muscle 4 12.5
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ASSOCIATION OF MODIFIED RODNAN SKIN SCORE WITH SYSTEMIC
MANIFESTATIONS
The systemic involvement in our patients with various ranges of Rodnan skin score is
shown in table 16. A significant association (p=0.026) was noticed between the
Rodnan skin score and interstitial lung disease. There was no association noticed
between the Rodnan skin score and oesophageal dysmotility or with oesophageal
reflux.
TABLE 16 -ASSOCIATION OF RODNAN SKIN SCORE WITH SYSTEMIC
MANIFESTATIONS
RODNAN SKIN
SCORE
INTERSTITIAL
LUNG  DISEASE
No (%)
OESOPHAGEAL
DYSMOTILITY
No (%)
OESOPHAGEAL
REFLUX
No (%)
<10 8(57.1) 3(21.4) 5 (35.7)
10-19 5(55.6) 4(44.4) 5(55.6)
>19 12(100) 2(16.7) 5(41.7)
TOTAL 25 9 9
P value 0.026 0.316 0.640
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Table 17 shows association of modified Rodnan skin score with type of the systemic
sclerosis. There was an increasing trend   between the Rodnan’s skin score and extent
of disease (χ2 =4.922 df =2 p = 0.086). This however was not statistically significant.
TABLE 17 -ASSOCIATION OF RODNAN’S SKIN SCORE WITH TYPE OF
DISEASE
RODNAN SKIN
SCORE
TYPE  OF DISEASE TOTAL
DIFFUSE
No.(%)
LIMITED
No.(%)
<10 11(78.6) 3(21.4) 14
10-19 9(100%) 0 9
>19 12(100%) 0 12
TOTAL 9 26 35
DERMOSCOPY
The various nail fold dermoscopic findings in our study population were noted
in table 18. The commonest dermoscopic feature was dilated capillaries (91.4%)
followed by dropouts (62.9%).
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TABLE 18 – DERMOSCOPY FEATURES
Feature Frequency (%) Percentage
Dilated Capillaries 32 91.4
Giant Capillaries 15 42.9
Avascular Areas 11 31.4
Capillary haemmorhages 16 45.7
Dropouts 22 62.9
The nail fold dermoscopic features present in diffuse and limited systemic sclerosis
are depicted in table 19. In the limited disease the commonest dermoscopic feature
was dilated capillaries with preserved capillary configuration.
TABLE 19 – DERMOSCOPY FEATURES - DIFFUSE VS LIMITED
Feature Diffuse Limited
Frequency Percentage Frequency Percentage
Dilated Capillaries 29 90.6 3 100
Giant Capillaries 14 43.8 1 33.3
Avascular Areas 11 34.4 0
Capillary hemorrhages 15 46.9 1 33.3
Dropouts 22 68.8 0
Table 20 shows the distribution of abnormal capillary patterns. In our study we
noticed single abnormal finding in 7 patients with commonest pattern being dilated
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capillaries, two abnormal findings in 11 patients with commonest pattern being
capillary dilatation with drop outs, three abnormal findings in 10 patients commonest
being capillary dilatation and drops outs with capillary haemorrhage or giant
capillaries and four abnormal findings in 5 patients and all five abnormal findings in
2 patients.
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TABLE 20 – DISTRIBUTION OF ABNORMAL DERMOSCOPY PATTERN
ABNORMAL DERMOSCOPY PATTERNS number Percentage
Single finding (n=7)
Dilated capillaries
Drop out
Avascular
4
2
1
11.4
5.7
2.9
Two findings(n=11)
Dilated capillaries and giant capillaries
Dilated capillaries and capillary hemorrhage
Dilated capillaries and dropout
2
1
8
5.7
2.9
22.9
Three findings( n = 10 )
Dilated capillaries, giant capillaries and capillary hemorrhage
Dilated capillaries, giant capillaries and avascular areas
Dilated capillaries, capillary hemorrhage and dropout
Dilated capillaries giant capillaries and dropouts
Avascular, dilated capillaries and capillary hemorrhage
2
1
3
3
1
5.7
2.9
8.6
8.6
2.9
Four findings (n= 5)
Dilated capillaries, giant capillaries, avascular areas, capillary
hemorrhage
Dilated capillaries, avascular, capillary hemorrhage and dropout
2
3
5.7
8.6
All findings(n=2)
Dilated capillaries, giant capillaries,avascular, capillary
haemmorhage, dropout
2 5.7
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Nail fold capillary pattern
The nail fold pattern was classified into early, active, late scleroderma pattern and
non specific pattern by Cutolo et al. The nail fold capillary patterns which were seen
in our study population are seen in table 21. Scleroderma pattern was present in
77.1% of the study population and non specific pattern was present in 22.9%.
Among the patients with scleroderma pattern 5 had early pattern, 15 had active
pattern and 7 had late pattern.
TABLE 21 –NAILFOLD CAPILLARY PATTERN
Capillary Pattern Frequency
Early 5
Active 15
Late 7
Non specific 8
Total 35
ASSOCIATION OF MEAN DURATION OF DISEASE WITH TYPE OF CAPILLARY
PATTERN
Table 22 depicts the mean duration of disease with type of capillary pattern. It shows
the mean duration of illness is less in patient with early scleroderma as compared to
patients with active and late pattern.
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TABLE 22– DERMOSCOPY PATTERN AND MEAN DURATION OF
DISEASE
DERMOSCOPY PATTERN MEAN DURATION(MONTHS)
Early 32.4+23.8
Active 44.80+30.4
Late 46.29+29.2
Non specific 44.75+43.5
ASSOCIATION OF TYPE OF DERMOSCOPY CAPILLARY PATTERN
WITH SYSTEMIC MANIFESTATIONS
The association of type of dermoscopic pattern with systemic manifestation are
shown in Table 23. In patients with interstitial lung disease the commonest
dermoscopy feature was active pattern followed by late pattern. Even though larger
proportion of patients with interstitial lung disease had scleroderma pattern, the
association was not statistically significant. This could possibly be due to smaller
sample size. In patient with oesophageal dysmotility the commonest observed pattern
was active with no statistically significant association. In oesophageal reflux, the
commonest observed pattern was active pattern followed by non specific pattern. In
patients with cardiac involvement active and late pattern were the commonest
observed patterns. All patients with muscular system involvement had scleroderma
pattern with commonest being the active type. As only one patient each had
pulmonary artery hypertension and renal involvement, these were not correlated.
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TABLE 23- ASSOCIATION OF TYPE OF DERMOSCOPY CAPILLARY
PATTERN WITH SYSTEMIC MANIFESTATIONS
Type of
scleroderma
Interstitial lung
disease
No(%)
Esophageal
Dysmotility
No(%)
Esophageal
reflux
No(%)
Cardiac
No(%)
Active 13(86.7) 6(40) 7(46.7) 2(13.3)
Early 3(60) 1(20) 2(40) 1(20)
Late 5(71.4) 0 2(28.6) 2(28.6)
Non-specific 4(50) 2(25) 4(50) 0
Total 25 9 15 5
p value 0.281 0.249 0.836 0.45
Table -24 shows the association of type of dermoscopy capillary pattern with
Raynaud’s phenomenon. There was no association between type of capillary pattern
and Raynaud’s phenomenon
TABLE 24 - ASSOCIATION OF TYPE OF DERMOSCOPY CAPILLARY
PATTERN WITH RAYNAUD’S PHENOMENON
Dermoscopy
capillary pattern
Raynauds
phenomenon Present
No(%)
Raynauds
phenomenon absent
(No%)
Total
Active 11(73.3) 4(26.7) 15
Early 5(100) 0 5
Late 4(57.1) 3(42.9) 7
Non-specific 3(37.5) 5(62.5) 8
Total 25 10 35
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χ2= 3.039 df=3. P = 0.644
INVESTIGATIONS
ANTI NUCLEAR ANTIBODY PATTERNS
ANA was positive in 31 patients and not done in 4 patients. The commonest type was
speckled (35.5%) followed by speckled and nucleolar (25.8%).
TABLE 25- ANA PATTERNS
Patterns of ANA Frequency (%)
Nucleolar 4 (12.9)
Speckled 11(35.5)
Speckled and nucleolar 8(25.8)
Not specified 8(25.8)
Anti CENP was positive in all the patients with limited disease. Anti Scl -70 was
positive in 19 (59.3%) of our study population.
COMPUTED TOMOGRAPHY - CHEST
Abnormal features in CT thorax were shown in table 26. The commonest feature was
interstitial lung disease which manifested as ground glass opacities or NSIP pattern.
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TABLE 26 – CT findings
CT findings Frequency(n-13)
Normal 3(23.1)
Interstitial lung disease 8(61.5)
Dilated oesophagus 2(15.3)
Liver heterogeneity 1(7.7)
INTERLEUKIN -6 LEVELS
Interleukin -6 was performed in a subset of 7 patients with scl-70 positive diffuse
systemic sclerosis. Of the 7 patients, 2 patients had elevated interleukin 6 levels.
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FIGURE 11- depigmented macules over the dorsa of hand
FIGURE 12 - salt and pepper pigmentation over the neck
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FIGURE 13 - digital scars over the finger tips
FIGURE 14 - neck sign
Prominence of
platysma
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FIGURE 15- Round finger Pad sign
FIGURE 16- Scarring alopecia with depigmentation – scalp
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FIGURE 17 - ulcers over right ankle
FIGURE 18 – pterygium inversum unguis
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FIGURE 19 - Mask like facies
FIGURE 20 - melanonychia – right thumb nail
FIGURE 21 – Early scleroderma pattern :dilated capillaries with normal capillary
configuration
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FIGURE 22 – Active scleroderma pattern: dilated capillaries, drop outs,
haemorrhage
FIGURE 23 – Active scleroderma pattern: giant capillaries, dilated capillaries ,
dropout, capillary haemorrhage
FIGURE 24 - Active scleroderma pattern : dilated capillaries, ramifications, drop out,
giant capillaries
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FIGURE 25 - Active scleroderma pattern: giant capillaries , drop out
FIGURE 26 - Active scleroderma pattern: dilated capillaries, bushy capillaries
haemorrhages,  avascular areas
FIGURE 27 - Active scleroderma pattern: dilated capillaries, bushy capillaries
haemorrhages,  avascular area
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FIGURE 28 - late scleroderma pattern : avascular areas with dilated capillaries
FIGURE 29 – late scleroderma pattern : Avascular areas with dilated capillaries
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DISCUSSION
Scleroderma is an autoimmune condition of unknown aetiology. It is characterised
by skin thickening and fibrosis of visceral organs including the lungs, gastrointestinal
tract, and heart. Raynaud's phenomenon and immune system activation is manifested
by presence of SSc-related antibodies, in particular anti-centromere antibodies and
anti-topoisomerase I (also called Scl-70) antibodies. (2) In the latest ACR – EULAR
classification nail fold dermoscopy is one of the criteria for the diagnosis of
scleroderma. (48) There are no prior studies on dermoscopic patterns in our Indian
setting. Hence we proposed to study the cutaneous profile and nail fold dermoscopy
of all patients who presented with scleroderma in our setting.
Thirty five patients were recruited in the study from February 2014 to September
2015. All patients with diffuse disease fulfilled the ACR criteria and patients with
limited disease had sclerodactyly with CENP antibody positivity.
Demographic profile
Male: female ratio
In our study there was a female preponderence with male to female ratio being 1:6.
This was similar to the study in Britain by Silman et al.(1:6) and with an Indian study
by Sharma et al. (1:5.2).(99)(8)However the female gender predisposition was higher
than the study in United States by Mayes et al.(1:4) and the study in Australia by
Robert Thomson et al. (1:4).(5)(10) It was lower than the study in Iceland by
Geirsson et al. (1:8) and the study in Japan by Tamaki et al. (1:14).(9) (11)
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Age
The mean age in our study was 36.29+ 12 years  which was almost similar to the
study done by Sharma et al and Ruangjutipopan et al., but lower than the study by
Reville et al.(78)(8)(5)
Duration of disease
The mean duration of our disease was 43.31+ 31.8  months which was similar to the
study done by Pradhan et al. but shorter than the study done by Sharma et al.(8)The
duration  of disease among the African American was 30+20 months  and whites was
21+ 18  months.(59)Our patients had a longer duration of  disease compared to the
studies.
Geographical distribution
In our study we observed that majority  of the patients(68%)  were from the eastern
region followed by the southern states. The patients from the northern, western and
central region were limited.
Type of disease
The prevalence of diffuse disease was higher in our study in comparison to the study
by Pradhan et al and Reville et al. The prevalence of  limited disease in our study was
less(9%) as compared to the study by Pradhan et al which was 29.1%. (59)(12)
The clinical features of our study were compared with clinical features in other
Indian studies in various geographical locations as depicted in table -27. There were
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no prior studies done on cutaneous manifestations in the eastern region of India.
Cutaneous sclerosis was present in 97.1% of individuals which was similar to the
studies by Sharma et al. and Krishnamurthy et al. and higher than the study by
Pradhan et al. Presence of Raynaud’s phenomenon was similar to the study by
Pradhan et al. The study by Sharma et al. had a higher prevalence(98.5%) and
Krishnamurthy et al.(28.2%) had a lower prevalence of Raynaud’s phenomenon.  The
lower prevalence in the study by Krishnamurthy et al. was attributed to the hot
climate. The prevalence of Raynaud’s  phenomenon in our study was higher as ours
being a tertiary centre caters to patients from all parts of India.
Pigmentary disturbances were higher in our study as compared to other studies.
(8)(50) Salt and pepper pigmentation was the commonest type of pigmentation in our
study as compared to hyperpigmentation in the study by Sharma et al. Digital ulcers,
gangrene, resorption of digits and flexion contractures were less common in our
study as compared to the other Indian studies. The commonest site of flexion
contracture was the fingers which was similar to the study by Sharma et al.
Telangiectasias were less common in our study as compared to the study by Sharma
et al.(26.8% vs 36.8%). Mean mouth opening in our study was higher
(43.97+13.66mm) as compared to the north Indian study in which mean mouth
opening was 24.6±19.01 mm.. Reduced mouth opening was present in 54.3%. Mean
value of modified Rodnan skin scores in our study was 16.66+ 10.9 which was lower
than the study by Sharma et al. and similar to the west. The decrease in Rodnan score
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in our study as compared to other Indian studies can be explained by the fact that
most patients were on prior treatment before coming to our centre. In our study upper
limb was the commonest site of cutaneous involvement and scelerodactyly was the
commonest manifestation. Round finger pad sign was present in 7 of our study
population with the commonest site being the ring finger. The commonest
manifestations in the nails were ragged cuticles which were seen in 65.7% and
pterygium inversum unguis which was seen in 17.1%. There were no studies from
India looking at nail manifestations in systemic sclerosis.
Leg ulcers were seen in 3 patients and cobblestone appearance over neck was seen in
one patient. Sclerodactyly was present in all patients with limited disease. Calcinosis
and telangiectasis, which are commonly associated with limited type of disease was
conspicuously absent in our subset of patients with limited disease. We had only 3
patients with limited disease and hence, a definite conclusion cannot be drawn. In the
limited disease all the patients had sclerodactyly. Facial involvement was present in
one patient who had beaked nose, radial furrows and inability to evert lower eyelid.
A significant association (p=0.026) was found between Rodnan skin score and
interstitial lung disease. This was in keeping with other studies which proved a
positive association between type and extent of disease and interstitial lung disease.
(12)(8)(50)
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TABLE 27 - CLINICAL FEATURES IN VARIOUS INDIAN STUDIES
Feature Our study Sharma et
al.
(8)
Krishnamurthy et
al.
(50)
Pradhan
et al.
(12)
No. of patients 35 100 78 110
Skin sclerosis 97.1 98.5 100 74.1
Raynaud’s
Phenomenon
71.4 98.5 28.2 76.5
Telangiectasia 28.6 36.8 - -
Pigmentary disturbance 94.3 91 73.1 -
Hyperpigmentation 45.7 88.1 - -
Salt and pepper
pigmentation
65.7 55.3 - -
Depigmentation 48.6 31.3 - -
Gangrene 2.9 6.7 - -
Flexion contracture 20 64.6 -
Digital ulcer 2.9 58.6 47.4 23.5
Resorption of digits 14.3 46.6 7.8
The clinical features in our study in comparison to various ethnic groups are depicted
in table -28. Our study had a greater prevalence of sclerosis as compared to study by
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Reville et al and similar to the study in Thailand by Ruangjutipopan et al. and Iraq by
Adhadh et al. Raynaud’s phenomenon was lower in our population in comparison to
western population, Iraq and Thailand. India has predominantly a tropical climate
and extends 22° 00' N and 77° 00' E and hence has a higher temperature which
probably contributes to the decreased prevalence of Raynaud’s phenomenon in our
study population. (100) Telangiectasia was lower in our studies as compared to the
western population and Iraq and higher than the African Americans and Thais. This
can be explained by the fact that telangiectasias could have been easier to view on a
background of fair complexion with Fitzpatrick skin type 2 and 3 compared to our
Fitzpatrick skin types 4 and 5. The commonest site was face in all the above
mentioned studies.
Pigmentary alteration was commoner in our study(94%) as compared to other
studies and much higher than the western population.  Pigmentary alterations were
also common among the African Americans and Iraqis. The types of pigmentary
disturbance seen in these populations were not mentioned. The prevalence of digital
ulcers and resorption in digits was lower in our study as compared to the western
population. This can be explained by the lower incidence of Raynaud’s phenomenon.
The commonest site of flexion contracture was fingers involving the DIP joint in our
study. To summarise pigmentatory disturbances was higher in our populations
whereas Raynaud’s phenomenon, digital ulcers and telangiectasia were less common
than in western population. (78)(59)(72)
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TABLE 28 - CLINICAL FEATURES IN VARIOUS ETHNIC GROUPS
Feature
Our
study
Iraq
(72)
Thailand
(78)
American
Whites
(59)
American
Hispanics
(59)
African
American
(59)
No of patients 35 75 222 79 54 58
Skin Sclerosis 97.1 96.5 100 46 61 62
Raynaud’s
phenomenon
71.4 100 94.1 86 93 96
Telangiectasia 28.6 58 9.5 53 61 14
Pigmentary
Disturbance
94.3 83 - 51 59 82
Hyperpigmentation 45.7 - - - - -
Salt and pepper
pigmentation
65.7 - - - - -
Depigmentation 48.6 - - - - -
Gangrene 2.9 - - - - -
Flexion
contracture
20 - - - - -
Digital ulcer 2.9 - 53.6 49 61 82
Resorption of
digits
14.3 - - 80 87 89
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The systemic manifestations in our study in comparison with other studies both
within India and outside India are shown in table -29. In our study the commonest
systemic manifestation was pulmonary involvement and the commonest presentation
being pulmonary fibrosis.  The prevalence of pulmonary involvement (74.3%) in our
study was mildly lower than the study by Pradhan et al. and higher than the study by
Sharma et al and the western population. (12) (8) Gastrointestinal involvement in our
study was comparable to the study by Sharma et al. and the western studies.(8) (59)
The prevalence of GI involvement was surprisingly much lower in the study by
Ruangjutipopan et al in Thailand and the study by Pradhan et al.(78)(12)The
commonest presentation of gastrointestinal involvement was gastroesophageal reflux
followed by oesophageal dysmotility. The prevalence of renal involvement in our
study(3.1%) was lower than all the other studies. The prevalence of renal
involvement was higher (25%) in the western population. (59)Cardiac involvement in
our study was similar to the study by Pradhan et al. Musculoskeletal involvement in
our study was lower as compared to the study by Pradhan et al.(12)
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TABLE 29 - SYSTEMIC INVOLVEMENT
System Our
Study
Sharma
et al
(8)
Pradhan et
al.
(12)
Iraq
(72)
American
Whites
(59)
American
Hispanic
(59)
African
American
(59)
Thailand
(78)
No. of
patients
35 75 110 75 79 54 78 222
Pulmonary 74.3 51.1 77.3 57.4 44.6 14 22 32
Renal 3.1 6 10.9 9 23 24 25 5.8
Cardiac 14.3 - 13.6 - - - - -
Gastro
Intestinal
68.6 70.2 7.3 - 62 63 71 41.9
Musculo
Skeletal
11.4 - 39.1 - - - - -
The nail fold dermoscopy findings in our study was compared with the findings in a
study by Dogan et al. In our study, nail fold dermoscopy showing scleroderma
pattern was seen in 77.1% of the patients. This was slightly lower than the study done
by Dogan et al. The commonest nail fold capillary pattern was dilated capillaries in
both the studies. The prevalence of dilated capillaries was 91.4% vs 49%. The
commonest nail fold pattern in both diffuse and limited type of disease was dilated
capillaries which was similar to the study by Dogan et al. In our study giant
capillaries and avascular pattern were seen in one patient with the limited disease.
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Scleroderma pattern was further divided into early, active and late pattern.
(97)(96)(18) Early pattern was seen in 5 patients, active in 15 and late in 7 patients
and non specific pattern was seen in 8 patients respectively. Active scleroderma
pattern was the commonest pattern seen in association with systemic manifestation.
None of the systemic manifestations showed a positive association with capillary
patterns. This observation was similar to the observations by Dogan et al. In our
study the commonest nail fold dermoscopy pattern seen with interstitial lung disease
was active scleroderma pattern (52%) followed by late scleroderma pattern (20%). In
our study, the patients with cardiac involvement the commonest patterns were active
scleroderma pattern (40%) and late scleroderma pattern (40%). Patients with
oesophageal reflux disease had active scleroderma pattern (46.7%) followed by non
specific pattern (26.7%) and patients with oesophageal dysmotility had active
scleroderma pattern (66.7%) followed by non specific pattern (22.2%).
The nail fold capillary changes noted in our study included capillary loop dilatation,
drop outs, giant capillaries, capillary haemorrhage and avascular areas. In our study
we noticed single abnormal finding in 7 patients, the commonest being dilated
capillaries. Majority of our patients (n=11, 31.4 %) had 2 abnormal findings closely
followed by 10 patients (28.6%) who had 3 abnormal nail fold findings.  All five
abnormal findings were seen in 2 patients. Hence, a combination of different
dermoscopic findings can be seen in the same patient. Further studies will be
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required to see if these dermoscopic patterns predict a particular systemic
involvement.(90)
INVESTIGATIONS
Antinuclear antibody positivity was seen in 88.6% of our patients which was similar
to the study by Sharma et al. (89.1%) and study by Pradhan et al.(85.5%). ANA
positivity was similar to that in the western population. It was lower in the study by
Adhadh et al.(67%). In our study the commonest type was speckled (35.5%)
followed by speckled and nucleolar(25.8%). This was lower than the prevalence of
speckled in the study by Sharma et al.(62.1%). The prevalence of both speckled and
nucleolar was much higher in our study as compared to the study by Sharma et al.
(25.8% vs 1.3%). Anti scl-70 was  positive in  59.3% which was mildly lower than
the study by Pradhan et al but higher than study by Sharma et al.(8)(12)
Interleukin -6 levels were elevated in 2 of the 7 patients tested with scl-70 positve
diffuse systemic sclerosis. It has been noted in other studies that IL-6 is associated
with increase in avascular areas in dermoscopy and a higher probability of digital
ulcers. (37) Studies have shown a correlation of IL-6 levels with skin fibrosis.
Further studies on serum IL-6 in systemic sclerosis will be required to establish
relationship of IL-6 with dermoscopic patterns and skin fibrosis and its potential role
as a therapeutic target.(35)(34)(39)
The commonest finding on CT thorax was ground glass opacities or NSIP (65.7%)
which was higher in our study as compared the study by Sharma et al. (45%)
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In our hospital based study, we tried to look at the cutaneous profile and nail fold
dermoscopy of patients presenting to us with scleroderma. In our study, we had a
female preponderance of patients with systemic sclerosis. The diffuse type of disease
was commoner and was present in 91% of our study population.  The mean duration
of disease was higher in our study as compared to the previous studies. Upper limb
was the commonest site of involvement with sclerodactyly being the commonest
manifestation. Cutaneous sclerosis and pigmentation was higher in our study
(97.1%). Raynaud’s phenomenon, digital ulcers, gangrene and flexion contractures
were less common in our study. The commonest systemic manifestation was
interstitial lung disease. There was a significant association found between Rodnan
skin score and interstitial lung disease. The commonest nail fold capillary
abnormality was dilated capillaries seen in 91.4% of our study population.
Scleroderma pattern was present in 77.1% of our study population with active pattern
in 15 patients. Interleukin-6 was elevated in 2 of 7 patients tested. Nail fold
dermoscopy is a useful tool for diagnosis, assessing disease severity and prognosis.
Further studies are required to study the role of interleukin -6 in systemic sclerosis.
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CONCLUSIONS
In our study of cutaneous profile and nail fold dermoscopy of patients with
scleroderma, we observed the following findings:
1. There was a female preponderance in our study population with a male to
female ratio of 1:6.
2. Mean duration of disease at presentation was 43.31+ 31.8  months.
3. There was a higher prevalence of diffuse type of disease(91%) in our study
population.
4. Cutaneous sclerosis was present in 97.1% of our study population with the
upper limb being the commonest site of involvement.
5. Pigmentary disturbances were commoner in our study(94.3%) as compared to
the western population. The commonest pigmentary abnormality was salt and
pepper pigmentation.
6. Prevalence of Raynaud’s phenomenon was 71.4%.
7. The prevalence of digital ulcers(2.9%), gangrene(2.9%) and flexion
contracture(20%) were lower in our study.
8. Prevalence of telangiectasia (26.8%) and calcinosis(8.65%) was lower in our
study.
9. Neck sign was seen in 57.1% of patients.
10. Round finger pad sign and pterygium inversum unguis was seen in 25.7% and
17.1% patients respectively.
11. The commonest systemic manifestation was interstitial lung disease (74.3%)
followed by gastrointestinal involvement (68.6%).
12. The prevalence of renal involvement(3.1%) was lower in our study.
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13. The commonest pattern in nail fold dermoscopy was dilated capillaries seen in
91.4% of our patients.
14. In nail fold dermoscopy scleroderma pattern was seen in 77.1% of our
patients, 5 patients with early pattern, 15 with active pattern and 7 with late
pattern.
15. More than one abnormal dermoscopic finding was seen in 80 % of our study
population. Presence of two abnormal findings was the commonest pattern
seen in 11 patients.
16. There was no statistically significant association between nail fold
dermoscopy patterns with systemic manifestations.
17. Early, active and late pattern of capillary pattern were associated with
increasing trend of disease duration but this was not of statistical significance.
18. Modified Rodnan skin score showed statistically significant positive
association with interstitial lung disease(p=0.026).
19. Interleukin-6 was performed in a subset of scl-70 antibody diffuse systemic
sclerosis and it was elevated in 2 of 7 patients.
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LIMITATIONS
1) The sample size was inadequate to delineate the association of nail fold
dermoscopic findings with the type of disease and systemic manifestations.
2) Mean value of megacapillaries and capillary density was not measured in our
study.
3) Interleukin -6 could be performed only on a subset of patients, hence a  larger
study will be required to correlate serum interleukin -6 levels with skin
severity scores.
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RECOMMENDATIONS
1. A  baseline dermoscopy should be performed for all patients with suspected
systemic sclerosis to predict the course of the disease as  early initiation of
therapy can prevent complications
2. Further studies are required to study nail fold capillary abnormalities in our
setting and also its association with systemic manifestations
3. Video morphometry studies are required to study capillary architecture and
inter capillary distance
4. Further studies and follow up are required to study the role of interleukin -6
levels in fibrosis in systemic sclerosis and its response with treatment
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ANNEXURE –I
AMERICAN COLLEGE OF RHEUMATOLOGY(ACR) CRITERIA
Major criteria
Symmetric proximal sclerosis extending beyond metacarpal phalangeal joint and
metatarsal joint
Minor criteria
1) sclerodactyly
2) digital pitted scars/loss of substance over finger pads
3) bibasilar fibrosis
ANNEXURE -II
Patient Information Sheet and consent forms
Study Title:Cutaneous Profile and nail fold dermatoscopy of  scleroderma  patient
Purpose of research:
Scleroderma is a disease for which the exact aetiology of which is not known. Scleroderma
predominantly affects the skin causing tightening. It can also affect the lungs, heart, gastro
intestinal system and blood vessels. In this study I intend to study the various skin manifestations
associated with the disease . Also a particular substance secreted by the white blood cells in our
body known as Interleukin 6 (IL-6) is known to be associated with the skin lesions in scleroderma. I
further intend to view the capillaries in the skin around the nails using a dermatoscope. This gives a
magnified image of the capillaries and  helps  to predict stage of the disease.
Expected duration of the Subject’s participation:
Only at the time of presentation of the patient at the Dermatology Unit - II OPD/ Rheumatology
OPD/ in-patients with  scleroderma. Patient will be adviced to come for follow up after 3 months
during which time a blood test will be done.
Description of the procedures:
This study would involve recording of the patient’s relevant details and detailed examination of
skin lesions. A dermatoscopy will be performed to view the capillaries around the finger nails. In
selected patients(patients with extensive skin involvement) a blood sample will be collected for
measurement of interleukin 6. Clinical photographs of the skin lesions may be taken.
Risks or discomforts to the Subject:
As the study does not include any trial treatment, there is no additional risk for the patient due to
participation in study. The patient will not incur any additional cost by taking part in the study.
Benefits to the Subject:
It may help in further management of the condition.
Benefits to others:
Information gathered from this study might help in the understanding of the cutaneous aspects of
scleroderma. An understanding of the role of IL 6  and nail fold dermatoscopy may help in future
contribute to exploration of potential treatment options as well as prognosis of scleroderma.
Confidentiality:
Only the investigators of this study will be able to access the patient’s medical records.  Patient’s
identity will not be revealed in any form or released to third parties or published.
Participation:
The patient’s participation in the study entirely voluntary and the patient is free to withdraw from
the study at any time, without stating any particular reason. Refusal to participate or withdrawal
from the study will not involve any penalty or loss of benefits to which the patient is otherwise
entitled.
Approximate number of Subjects enrolled in the study – 100
Contact person:Dr Priya Sara Kuryan, PG registrar, Department of Dermatology, leprosy and
Venerology Unit II, CMC, Vellore
Phone – 04162282054
email – derm@cmcvellore.ac.in
ANNEXURE – III
Cutaneous Profile and nail fold dermatoscopy of  scleroderma  patients
and serum interleukin 6 levels correlation with modified Rodnan skin
severity score
ProformaDate ____________ Sl.noName ____________________   CMCH no. ____________  Age _________    Sex _____Address
Contact no
Type of disease: Diffuse/Limited          Duration of disease   _______monthsDuration of Raynaud’s phenomenon _____ months Duration of sclerosis ____________ monthsPast History of skin lesions Yes/ No If yes, details ______________________Duration of treatment __________ monthsTreatment details
Drug Dose Duration
Topical
SystemicSteroidsMycophenolate mofitelAzathioprineCyclophosphamideHydroxychloroquineOthers

Skin lesions Present/Absent
FaceRadial furrowsBeaked noseInability to evert lower eyelidSmoothening of forehead ExpressionMouth opening mmMask like faciesPeri-orbital Edema
HandDigital ulcersDigital pitted scarsPitting edema of fingersRound finger pad signFlexion contracturesSclerodactylyGangreneDystrophic nailsRagged cuticlesResorption of phalangesPterygium inversium unguisCobble stone appearance
LegLeg ulcersLivedo reticularisAtrophie blancheGangreneRaynaud’s phenomenonNeck signOthers
Skin lesions Present/Absent if present siteSclerosis
Calcinosis
Telangiectasia
Hyper pigmentation
Salt and pepper pigmentation
Hypopigmentation
Nail fold DermatoscopyRight handFindings Thumb Index finger Middle finger Ring finger Little fingerNormalcapillaryconfigurationDilatedcapillaryloopsGiantcapillariesCapillaryhaemmorhageAvascularareaDrop out
Left handFindings Thumb Index finger Middle finger Ring finger Little fingerNormalcapillaryconfigurationDilatedcapillaryloopsGiantcapillariesCapillaryhaemmorhageAvascularareaDrop out
Systemic manifestationsSystemic signs Present/absent
GIOesophageal dysmotilityOesophageal refluxOthers
RespiratoryInterstitial lung diseasePulmonary artery hypertension
Cardiac
Renal
Muscles
Others
InvestigationsInvestigation ResultANAAnti- centromere antibodyAnti – topo isomerase antibodyAnti RNP antibodyEchoHRCT chest
DateSerum interleukin-6Rodnan’s skin skin score

UniqueKey serialno cmcno age sex TYPEOFDISEASE DURATIONOFDISEASEINMONTHS DURRAYNAUDS
1 35 898478 52 FEMALE DIFFUSE 24 6
2 34 842145 31 FEMALE DIFFUSE 24 24
3 33 143885 17 FEMALE DIFFUSE 24 20
4 32 895460 33 MALE DIFFUSE 6 0
5 31 172041 36 FEMALE DIFFUSE 96 60
6 30 62462 49 FEMALE DIFFUSE 72 60
7 29 790621 31 FEMALE DIFFUSE 9 9
8 28 983059 39 FEMALE DIFFUSE 48 36
9 27 56748 26 FEMALE LIMITED 30 0
10 26 798049 29 FEMALE DIFFUSE 24 24
11 25 729888 37 FEMALE DIFFUSE 60 0
12 24 993776 29 FEMALE DIFFUSE 36 0
13 23 18099 36 FEMALE DIFFUSE 12 3
14 22 743938 21 MALE DIFFUSE 12 12
15 21 417859 24 MALE DIFFUSE 29 29
16 20 747687 27 FEMALE DIFFUSE 4 6
17 19 778021 48 MALE DIFFUSE 120 0
18 18 494627 50 FEMALE DIFFUSE 22 22
19 17 612549 56 FEMALE DIFFUSE 36 0
20 16 888727 44 MALE DIFFUSE 120 60
21 15 766436 52 FEMALE DIFFUSE 60 50
22 14 70578 20 FEMALE DIFFUSE 12 12
23 13 389974 43 FEMALE DIFFUSE 72 72
24 12 716214 34 FEMALE DIFFUSE 72 72
25 11 6445 43 FEMALE LIMITED 60 0
26 10 161638 20 FEMALE DIFFUSE 60 0
27 9 567629 38 FEMALE DIFFUSE 48 0
28 8 65452 22 FEMALE DIFFUSE 6 0
29 7 29181 28 FEMALE DIFFUSE 18 18
30 6 149926 36 FEMALE DIFFUSE 66 60
31 5 96878 36 FEMALE DIFFUSE 60 48
32 4 129126 53 FEMALE LIMITED 24 18
33 3 1347235 25 FEMALE DIFFUSE 18 12
34 2 206143 62 FEMALE DIFFUSE 36 36
35 1 572791 43 FEMALE DIFFUSE 96 72
DURSCLEROSIS PASTHISTORYOFSKINLESIONS DURATIONOFTREATMENT RADIALFURROWS BEAKEDNOSE
24 No 7 Yes Yes
24 No 0 Yes Yes
24 No 6 Yes Yes
6 No 3 Yes Yes
96 No 2 No No
72 No 6 Yes Yes
8 No No Yes
48 No 36 No No
0 No 0 No No
12 No 6 No Yes
0 No 36 Yes Yes
0 No Yes Yes
3 No 10 Yes Yes
12 No 2 Yes Yes
29 No 24 Yes Yes
0 No 0 No No
120 No 12 Yes Yes
20 No 13 Yes Yes
36 No 24 Yes Yes
120 No 2 No No
60 No 48 Yes Yes
12 No 8 No No
72 No 0 Yes Yes
72 No 6 Yes Yes
6 No 0 Yes Yes
60 No 0 Yes Yes
48 No 36 Yes Yes
6 No 0 Yes Yes
18 No 1 Yes Yes
66 No 36 Yes Yes
60 No 0 Yes Yes
24 No 18 No No
18 No 2 No No
36 No 0 Yes Yes
96 No 48 Yes Yes
INABILITTYTOEVERTLOWEREYELID SMOOTHENINGOFFOREHEADEXPRESSION MOUTHOPENINGINMM
No No 20
Yes Yes 20
Yes Yes 30
Yes Yes 30
No No 30
Yes Yes 30
Yes Yes 30
Yes No 32
No No 32
Yes Yes 35
Yes Yes 35
Yes No 38
Yes Yes 40
Yes No 40
Yes Yes 40
No No 40
Yes Yes 42
No No 46
No No 50
Yes Yes 50
Yes No 50
No No 50
Yes Yes 50
Yes Yes 52
No No 56
No No 60
Yes Yes 60
Yes No 60
Yes Yes 60
Yes No 60
Yes Yes 60
Yes No 63
No No 64
Yes Yes 64
Yes Yes 20
MASKLIKEFACIES PERIORBITALEDEMA DIGITALULCERS DIGITALPITTEDSCARS PITTINGEDEMAOFFINGERS
No No No Yes No
Yes No No Yes No
Yes No No Yes No
No No No No No
No No No No No
Yes No No Yes No
Yes No No Yes No
No No No Yes No
No No No No No
No No Yes Yes No
Yes No No Yes No
No No No No Yes
Yes No No Yes No
No No No Yes No
Yes No No Yes No
No No No No Yes
Yes No No Yes No
Yes Yes No Yes No
No No No No No
No No No No No
No No No Yes No
No No No Yes No
No No No No No
No No No Yes No
No No No No No
No No No No No
Yes No No No No
No No No No No
Yes No No No No
Yes No No No No
Yes No No Yes No
No No No No No
No No No Yes No
Yes No No No No
No No No No No
state ROUNDFINGERPADSIGN FLEXIONCONTRACTURES SCLERODACTYLY GANGRENE
sikkim Yes No Yes No
west bengal No No Yes No
tamilnadu No Yes Yes No
ap No No Yes No
bangladesh No No Yes Yes
jharkhand No No Yes No
west bengal No Yes Yes No
jharkhand Yes No Yes No
kerala No No Yes No
assam No No Yes No
west bengal Yes Yes No No
tamilnadu Yes No Yes No
kerala Yes No Yes No
west bengal No No No No
west bengal Yes Yes Yes No
west bengal No No Yes No
jharkand Yes No Yes No
west bengal Yes No Yes No
tamilnadu No No Yes No
ap Yes No Yes No
west bengal No No No No
jharkhand Yes No Yes No
tamilnadu No No Yes No
west bengal Yes Yes No No
ap No No No No
jharkhand No Yes Yes No
chandigarh No No Yes No
tamilnadu No No Yes No
west bengal No No Yes No
west bengal No No Yes No
west bengal No No Yes No
tamilnadu No No Yes No
bangladesh No No Yes No
west bengal No No Yes No
west bengal No Yes Yes No
DYSTROPHICNAILS RAGGEDCUTICLES RESORPTIONOFPHALANGES PTERYGIUMINVERSUMUNGUIS
No No No No
No Yes No Yes
No Yes No No
No No No No
No No No No
No Yes No No
Yes Yes No No
No Yes No Yes
No No No No
No Yes Yes Yes
No Yes Yes No
No Yes No Yes
Yes Yes No No
No Yes No No
No Yes Yes Yes
No No No No
No Yes Yes No
No Yes No No
No No No No
No Yes Yes No
No No No No
No No No No
No Yes No No
Yes No No No
No Yes No No
No No No No
No Yes No No
No Yes No No
Yes Yes No No
No Yes No No
No Yes No Yes
No No No No
No Yes No No
No Yes No No
No No No No
COBBLESTONEAPPEARANCE LEGULCERS LIVEDORETICULARIS ATROPHIEBLANCHE GANGRENE1
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No Yes No Yes No
No No No No No
No No No No No
No No No No No
No No No No No
Yes No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No Yes No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No Yes No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
RAYNAUDSPHENOMENON NECKSIGN OTHERS ifyessite ifyessitecont ifyessitegangrene sclerosis site1
No No No Yes face
Yes Yes Yes Yes face
Yes Yes No elbow Yes face
No Yes No Yes upper limb
Yes No Yes index, middle R Yes chest
Yes Yes No Yes face
No Yes No R hand Yes face
No Yes No R ring Yes face
No No No Yes upper limb
Yes Yes No Yes face
No No No ring R L little Yes upper limb
Yes Yes No ring R Yes face
No Yes No index Yes face
Yes Yes Yes Yes face
Yes Yes No Yes upper limb
No No No Yes upper limb
No No No Yes upper limb
Yes No Yes middle L Yes upper limb
No Yes No Yes abdomen
No Yes No R ring Yes face
No Yes No No
No Yes Yes index R Yes face
Yes Yes No Yes face
Yes No No Yes upper limb
No No No Yes upper limb
No Yes No hands Yes face
No No No Yes upper limb
No No No Yes face
No No No Yes upper limb
No No Yes Yes upper limb
No Yes Yes Yes upper limb
No No No Yes upper limb
No Yes No Yes face
No No No Yes upper limb
No Yes No finger Yes upper limb
site2 site3 site4 calcinosis sitecalcinosis telangiectasia ifyessitetelangectasia
chest abdomen upper limb No No
upper limb lower limb No Yes R cheek
upper limb lower limb No No
lower limb No No
abdomen upper limb lower limb No Yes cheek
chest upper limb lower limb No No
upper limb lower limb chest No No
upper limb lower limb No Yes cheek
No No
upper limb No No
lower limb No No
upper limb No No
upper limb lower limb No No
upper limb No No
lower limb No No
No Yes R cheek
lower limb chest back No Yes face,cheek
lower limb Yes Yes cheek
upper limb lower limb No No
upper limb lower limb Yes Yes r cheek
No No
chest upper limb lower limb No No
upper limb No No
lower limb No No
No No cheek
upper limb lower limb No No
No Yes cheek and palm
chest upper limb abdomen No No
No No
No No
No No
lower limb face No No
upper limb lower limb back No Yes cheeks
No No
face chest Yes knuckle Yes cheeks
hyperpigmentation ifyessitehyperpigmentation saltandpepperpigmentation
No No
Yes trunk,UL,LL Yes
No Yes
Yes face, neck,UL Yes
Yes UL,LL Yes
No No
No Yes
Yes face,trunk,UL Yes
Yes generalised Yes
Yes face,ear,neck,hands Yes
Yes UL,LL Yes
No No
No Yes
Yes arms Yes
Yes FACE Yes
Yes forearm No
Yes diffuse Yes
No Yes
No Yes
No Yes
No No
Yes dorsum if hand Yes
No No
Yes face,chest No
Yes face,UL No
Yes trunk UL LL No
No No
No Yes
Yes generalised No
No Yes
No Yes
No Yes
No Yes
No Yes
No No
ifyessaltandpeppper hypopigmentation ifyessitehypopigmentation
Yes eyebrow, nose, external ear, periorbital
scalp Yes trunk,UL,LL
earlobe,neck,UL,scalp No
retroauricular,occiputal,napeof neck Yes pinna,fingers
back,neck Yes hand,feet
No
wrist No
scalp,neck,back Yes LL
back,arm,hands No
back,retroauricular Yes L eyelid
chest,abdo,knee No
Yes ear,neck
face,chest,hand Yes bacl
CHEST,BACK,l ARM Yes L eyelid, perioral
face,back,trunk No
No
face neck UL No
chest,back,scalp Yes right fingers
forehead,neck,scalp,UL No
chest No
Yes back,neck
forearm Yes face
Yes neck,chest
No
No
Yes face
No
chest ll No
No
back Yes neck chest
retroauricular hair line No
back Yes waist
face neck No
forehead chest forearm shin No
Yes dorsa of hand
othersspecify normalcapillaryconfigurationthumb normalcapillaryconfigurationindex
No No
melasma No No
No No
No No
tinea corporis No No
No No
No No
No No
No No
Yes No
Yes No
No No
No No
Yes No
No No
No Yes
No No
Yes No
No No
No No
Yes Yes
Yes Yes
Yes Yes
No No
Yes No
No No
No No
No No
No No
melanonychia Yes No
scarring alopecia No No
Yes Yes
No No
No No
No No
normalcapillaryconfigurationring normalcapillaryconfigurationlittle dilatedcapillaryloopsthumb
No No Yes
No No No
No No Yes
No No No
No No No
No No Yes
No No Yes
No No Yes
No No Yes
No No Yes
No Yes No
No No No
No No Yes
No Yes No
No Yes No
Yes Yes No
No No No
No No Yes
Yes No Yes
No No No
No No No
No No No
No No No
No No No
Yes Yes No
No No Yes
No No Yes
No No Yes
No No Yes
Yes Yes No
No No Yes
No No No
No No No
No No No
No No Yes
dilatedcapilllaryloopsindex dilatedcapillaryloopsmiddle dilatedcapillaryloopslittle giantcapillariesthumb
Yes No No No
Yes Yes No No
No No Yes No
No No No No
No Yes No No
No Yes Yes No
Yes No No No
Yes No No No
Yes No No No
No Yes No No
No Yes No No
Yes Yes No No
Yes No No No
Yes Yes No No
No No No No
No No No No
Yes Yes No No
Yes Yes No No
No No No No
No Yes No No
Yes Yes No No
No No No No
No Yes No No
Yes No No No
Yes No No No
Yes No No No
Yes No No No
Yes No Yes No
Yes No No No
Yes Yes No No
Yes No No No
Yes Yes No No
No Yes Yes No
No Yes No Yes
Yes No No Yes
dilatedcapillariesring giantcapillariesindex giantcapillariesmiddle giantcapillariesring giantcapillarieslittle
No No Yes No No
No No No No No
No No No No No
No No No No No
Yes No No No No
Yes No No No No
No No No No No
No No No Yes No
No No Yes No No
No No Yes No No
No No No Yes No
No No No No No
No No Yes Yes No
No No No No No
No No No No No
No No No No No
No No No No No
No No No Yes No
No No No No No
No No No No No
Yes No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
No No No No No
Yes Yes No No No
No No No No No
No No No No No
No No No No No
No No No No No
Yes No No No No
Yes No No No No
No No No No No
capillaryhaemmmmorhagethumb capillaryhaemmorhageindex capillaryhaemmorhagemiddle
No No No
No No No
No No No
No No No
No No No
No Yes Yes
No No Yes
No Yes Yes
Yes Yes No
Yes No No
No No No
No No No
No No No
No Yes Yes
No No No
No No No
No No Yes
No No Yes
Yes No No
No No No
No No No
No No No
No No No
No No No
No No No
No No Yes
No Yes Yes
No No No
No No No
No No Yes
No Yes Yes
No No No
No No No
No No No
No Yes No
capillaryhaemmmorhagering capillaryhaemmorhagelitttle Avascularareathumb avascularareaindex
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
Yes No No No
No No No No
Yes Yes No No
Yes No No No
No No No Yes
No No No No
No No No No
No No No No
No No No No
No No No No
Yes No No No
Yes No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
Yes Yes No No
No No No No
No No No No
No No No No
No Missing No No
avascularareamiddle avasculararearing avasculararealittle othersright othersrightindex othersrightmiddle
No No No No No No
No No No No No No
No No No No No Yes
No No No Yes No No
No No No No No No
No No No No Yes Yes
No No Yes Yes Yes No
No No No No No No
No No No No No No
No No No No Yes Yes
Yes No No No No No
No No No No No No
No No No No No No
No No No Yes Yes No
No Yes No No No No
No No No No No Yes
No No No No No No
No No No No No No
No No No No No No
No No No No No No
No No No No Yes Yes
No No No No No Yes
No No No No No No
No No No No Yes No
No No No No No No
No No No No No No
Yes No No No Yes Yes
No No No No Yes Yes
No No No No No Yes
No No No No Yes No
No No No Yes Yes No
No No No No No No
No No No Yes Yes Yes
No No No No No Yes
Yes Yes Yes No No No
othersrightring othersrightlittle normalcapilllaryconfigurationthumbleft normalcapillaryconfigurationindex1
No No No No
Yes Yes No No
Yes No No No
No Yes Yes No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No Yes
No No Yes No
No No No No
No No No No
Yes Yes No No
Yes No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
Yes No No No
Yes No No Yes
Yes No No No
No No Yes Yes
No No No No
No Yes No No
Yes No No No
Yes No No No
No No Yes Yes
No No No No
No No Yes No
No No No No
Yes No No No
No No No No
normalcapillaryconfigurationmiddlelt normalcapillaryconfigurationringlt normalcapillaryconfigurationlittle1
No No No
No No No
No No No
Yes Yes No
No No No
No No No
No No No
No No No
No No No
No No Yes
No No No
No No No
No No No
No Yes No
No No Yes
No Yes Yes
No No No
No No No
No No No
No No No
No No No
No No No
Yes No No
No No No
Yes Yes Yes
No No No
No No No
No No No
No No No
No No No
No No No
No No No
No No No
No No No
No No No
dilatedcapillaryloops dilatedcapillaryloopsindexlt dilatedcapilllaryloosmiddlelt dilatedcapillaryloopsringlt
Yes Yes No No
Yes Yes No No
No No No No
No No No No
Yes Yes No No
Yes Yes No Yes
Yes No No Yes
No Yes Yes No
Yes Yes No No
No Yes Yes Yes
No Yes No Yes
No No Yes Yes
Yes Yes No No
Yes Yes Yes Yes
No No No No
No No No No
No Yes Yes No
No No No No
Yes Yes Yes No
No Yes Yes No
No No No No
Yes Yes No No
Yes No No No
Yes Yes No No
No No No No
No No No No
Yes Yes No No
Yes Yes No No
Yes Yes No No
No No Yes Yes
No Yes Yes Yes
No Yes Yes No
No Yes Yes No
Yes Yes No No
Yes Yes No No
dilatedcapillaryloopslittlelt giantcapillariesthumbleft giantcapillariesindexlt giantcapillariesmiddlelt
No No No Yes
No No No No
No No No No
No No No No
No No No No
Yes No No No
No No No No
Yes No No No
Yes No No No
Yes Yes No No
Yes No No No
No No No No
No No No Yes
Yes No No No
No No No No
No No No No
No No Yes Yes
No No No No
No Yes Yes Yes
No No No No
No No Yes No
No Yes Yes Yes
No No No No
No No No No
No No No No
No No No No
No Missing No No
No No No No
No No No No
Yes No No No
No No No No
No No No No
No No No No
Yes No No No
No No No No
giantcapillariesringlt giantcapillarieslittlelt normalcapillaryconfigurationmiddle1
Yes No No
No No No
No No No
No No No
No No No
No No No
No No No
Yes No No
No No No
No Yes No
No No No
No No No
No No No
No No No
No No Yes
No No No
No No No
No No No
Yes Yes No
No No No
No No No
Yes Yes No
No No No
No No No
No No Yes
No No No
No No No
No No No
Yes No No
No No No
No No No
No No No
No No No
No No No
No No No
capillaryhaemmorhagethumblt capillaryhaemmmorhageindexlt capillaryhaemmorhagemiddlelt
No No No
No No No
No No No
No No No
No No No
No No Yes
Yes Yes No
No No Yes
No Yes Yes
No No No
No No No
No No No
No No No
No No No
No No No
No No No
No No No
No No Yes
No No No
No No No
Yes No No
No No No
No No No
No No No
No No No
No Yes Yes
No No Yes
No Yes Yes
No No No
Yes Yes Yes
Yes Yes No
No No No
No No No
No No No
Yes Yes Yes
capillaryhaemmorhageringlt capiilaryhaemmorhagelitttlelt avasculatltthumb avasculatltindex
No No No No
No No No Yes
No No No No
No No No No
No No No No
Yes No No No
No No No No
No No No No
Yes No No No
Yes Yes No No
No No No No
No No No No
No No No No
Yes No Yes Yes
No No No No
No No No No
Yes No No No
Yes No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
Yes No No No
No No No No
No No No No
No No No No
No No No No
No No No No
No No No No
Missing No No No
No No No No
avascularltmiddle avascularltring avascularltlittle othersltthumb othersltindex othersltmiddle othersltring
No No No No No No No
No No No No No No Yes
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rodnansskinscoredate rodnansskinscoredate2 rodnansskinscore1 rodnansskinscore2
05-08-2014 23
13-04-2015 24
14-02-2015 48
15-07-2015 15
12-03-2015 16
14-03-2015 8
01-02-2014 29
13-11-2014 25
01-10-2014 4
17-02-2015 16
22-11-2014 25
04-05-2015 10
31-07-2104 20
26-11-2014 31
20-03-2014 10
25-02-2014 4
15-03-2014 17
20-03-2014 28
02-10-2014 7
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09-07-2015 0
20-10-2015 26
16-10-2014 8
14-10-2014 15
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27-11-2014 12
27-02-2015 10
20-04-2015 15
30-04-2015 10
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वषय के लए सू चत सहम त फॉम का ा प
एक शोध अ ययन म भाग लेने के लए सू चत सहम त फॉम
अ ययन शीषक: Cutaneous ोफ़ाइलऔर नाखून सशंो धत Rodnan वचा गभंीरता कोर के साथ 6 तर
सहसबंधं इंटर यू कन scleroderma रो गय और सीरम क वचा का लसगनुा.
अ ययन सं या: ____________
वषय के थमा र : __________________ रोगी का नाम:
_________________________________________
ज म /आयु क त थ : ___________________________
( वषय)
( म ) ममने पढ़ा और समझा उपरो त अ ययन के लए ____________ दनां कत जानकार शीट और सवाल
पछूने का अवसर मला है क है क इस बात क पिु ट .
( ii) म अ ययन म मेर भागीदार विै छक हैऔर मअपने च क सा देखभाल या भा वत कया जा रहा काननूी
अ धकार के बना , कसी भी कारण बताए, कसी भी समय म वापस लेने के लए वतं हँू क समझते ह.
( iii) म च क सीय पर ण के ायोजक , ायोजक क ओर से काम कर रहे अ य लोग ,आचार स म तऔर
नयामक अ धका रय वतमान अ ययन के सबंधं मऔर कसी भी आगे अनसुधंान म दोन मेरे वा य रकॉड को
देखने के लए मेर अनमु त क ज रत नह ं होगी समझते ह क म पर ण से वापस लेने , भले ह यह करने के सबंधं
मआयोिजत कया जा सकता है . म इसका उपयोग करने के लए सहमत ह . हालां क, मअपनी पहचान तीसरे प
को जार या का शत कसी भी जानकार म नह ं बताया जाएगा क समझते ह.
( चतथु ) म इस तरह का इ तमेाल केवल वै ा नक उ दे य (ओ)ं के लए है, बशत क इसअ ययन से उठता है क
कसी भी डटेा या प रणाम के इ तमेाल को तबं धत करने के लए सहमत नह ं है.
( v)म उपरो त अ ययन म भाग लेने के लए सहमत ह.
( vi)म सं हत र त का नमनूा कसी भी भ व य के अनसुधंान म इ तमेाल कया जा सकता है क इस बात से
सहमत .
वषय /काननूी तौर पर वीकाय के ह ता र (या अगंठेू का नशान )
दनांक: _____ / _____ / ______
ह ता रकता का नाम: _________________________________ ह ता र:
या
त न ध: _________________
दनांक: _____ / _____ / ______
ह ता रकता का नाम: _________________________________
अ वेषक के ह ता र: ________________________
दनांक: _____ / _____ / ______
अ ययन जांचकता का नाम: _________________________
गवाह का ह ता र : ___________________________
दनांक: _____ / _____ / _______
नामऔर गवाह का पता: ______________________________
 
 
 
  

রাগীর তথ প ক
ািড িশেরানাম:
Cutaneous াফাইল এবং scleroderma রাগীেদর ভাঁজ dermatoscopy এবং িসরাম Interleukin থাকা
6 মা া বার পিরমািজত Rodnan চামড়া তী তা ার সে সংগিত
গেবষণার উে শ :
Scleroderma যা স ক aetiology পিরিচত না হয় , যার জন এক রাগ . Scleroderma ধানত
জারদার যার ফেল ক ভািবত কের. এ ফুসফুস, হাট, gastro অে র িসে ম এবং র জাহাজ ভািবত
করেত পাের. এই গেবষণায় আিম রােগর সে যু িবিভ চামড়া কাশ অধ য়ন মন করা. এছাড়াও করা
Interleukin 6 (আইএল -6 ) নােম পিরিচত আমােদর শরীেরর রে র তকিণকা ারা িনঃসৃত এক
িবেশষ পদাথ scleroderma চামড়ার ত সে যু করা হয়.আিম আরও এক dermatoscope ব বহার
কের নখ ায় চামড়ায় capillaries দখেত মন করা. এই capillaries এক িববিধত িচ দয় এবং
রােগর পযােয় ভিবষ াণী করেত সাহায কের.
িবষেয়র অংশ হণ ত ািশত সময়কাল :
ধু Dermatology ইউিনট এ রাগীর উপ াপনার সময় - scleroderma সে ি তীয় OPD /
বাতেরাগসং া OPD / ইন রাগীেদর . রাগীর র পরী া করা হেব , যা সময় 3 মাস পের অনুসরণ আপ
আসেত adviced করা হেব না.
প িত বণনা :
এই গেবষণায় রাগীর াসি ক িববরণ এবং েকর ত িব ািরত পরী া রকিডং জিড়ত হেব. এক
dermatoscopyআঙুল নখ ায় capillaries দখেত স ালন করা হেব . িনবািচত রাগীেদর ( ব াপক
চামড়া জিড়ত রাগীেদর ) এক রে র নমুনা সং হ Interleukin 6 পিরমােপর জন সং হ করা হেব.
েকর ত ি িনকাল ফােটা াফ নওয়া হেত পাের .
ঝঁুিক বা িবষয় discomforts :
গেবষণায় কােনা ায়াল িচিক সা অ ভু নয় , গেবষণায় অংশ হণ কারেণ রাগীর জন কান অিতির
ঝঁুিক নই. রাগীর গেবষণায় অংশ হণ কের কান অিতির খরচ বহন করেব না.
িবষয় সুিবধাসমূহ:
এ অব ার আরও ব ব াপনায় সাহায করেত পাের.
অন েদর সুিবধাসমূহ:
এই গেবষণায় থেক সং হ করা তথ scleroderma এর cutaneous িদক বুঝেত সাহায করেত পাের .
এক আইএল 6 ভূিমকা বাঝার এবং ভাঁজ dermatoscopy থাকা স াব িচিক সা অপশন অে ষণ
সইসােথ scleroderma এর পূবাভােসর অবদান ভিবষ েত সাহায করেত পাের.
গাপনীয়তা :
ধু এই গেবষণা তদ কারীরা রাগীর িচিকৎসা রকড অ াে স করেত স ম হেত হেব. রাগীর পিরচয়
কােনা আকাের কাশ করা বা তৃতীয় পে র মুি বা কাশ করা হেব না .
অংশ হণ :
স ূণ ােসবী গেবষণা এবং রাগীর রাগীর অংশ হণ কান িনিদ কারণ ছাড়াই জানায় , য কােনা
সময় গেবষণা থেক িনেজেক ত াহার করার িবনামূেল . অংশ হেণর বা গেবষণা থেক সের আসায়
অ ীকার যা রাগীর অন থায় এনটাইেটল করা হয় বিনিফট কান শাি বা হািন হেব না.
িবষয় আনুমািনক সংখ া গেবষণা মেধ নাম নিথভু - 100
যাগােযাগ ব ি : ডাঃ Priya সারা Kuryan , PG রিজ ার , Dermatology , ও Venerology
ইউিনট ি তীয়, CMC , Vellore িবভাগ
ফান - 04162282054
ইেমইল - derm@cmcvellore.ac.in
